National Cancer Institute CARCINOGENESIS Technical Report Series No. 126 1978

BIOASSAY OF 2,5-TOLUENEDIAMINE SULFATE FOR POSSIBLE CARCINOGENICITY

CAS No. 6369-59-1

NCI-CG-TR-126

U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE Public Health Service National Institutes of Health



ı

BIOASSAY OF

2,5-TOLUENEDIAMINE SULFATE

FOR POSSIBLE CARCINOGENICITY

Carcinogenesis Testing Program Division of Cancer Cause and Prevention National Cancer Institute National Institutes of Health Bethesda, Maryland 20014

U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE Public Health Service National Institutes of Health

.

DHEW Publication No. (NIH) 78-1381

REPORT ON THE BIOASSAY OF 2,5-TOLUENEDIAMINE SULFATE FOR POSSIBLE CARCINOGENICITY

CARCINOGENESIS TESTING PROGRAM DIVISION OF CANCER CAUSE AND PREVENTION NATIONAL CANCER INSTITUTE, NATIONAL INSTITUTES OF HEALTH

FOREWORD: This report presents the results of the bioassay of 2,5-toluenediamine sulfate conducted for the Carcinogenesis Testing Program, Division of Cancer Cause and Prevention, National Cancer Institute (NCI), National Institutes of Health, Bethesda, Maryland. This is one of a series of experiments designed to determine whether selected chemicals have the capacity to produce cancer in animals. Negative results, in which the test animals do not have a significantly greater incidence of cancer than control animals, do not necessarily mean the test chemical is not a carcinogen because the experiments are conducted under a limited set of circumstances. Positive results demonstrate that the test chemical is carcinogenic for animals under the conditions of the test and indicate a potential risk to man. The actual determination of the risk to man from animal carcinogens requires a wider analysis.

<u>CONTRIBUTORS</u>: This bioassay of 2,5-toluenediamine sulfate was conducted by Mason Research Institute, Worcester, Massachusetts, initially under direct contract to the NCI and currently under a subcontract to Tracor Jitco, Inc., prime contractor for the NCI Carcinogenesis Testing Program.

The experimental design was determined by the NCI Project Officers, Dr. J. H. Weisburger (1,2) and Dr. E. K. Weisburger (1). The principal investigators for the contract were Dr. E. Smith (3) and Dr. A. Handler (3). Animal treatment and observation were supervised by Mr. G. Wade (3) and Ms. E. Zepp (3).

Histopathologic examinations were performed by Dr. D. W. Hayden (3), Dr. A. S. Krishna Murthy (3), Dr. A. Russfield (3), and Dr. D. S. Wyand (3) at the Mason Research Institute, and the diagnoses included in this report represent the interpretation of these pathologists. Histopathology findings and reports were reviewed by Dr. R. L. Schueler (4).

Compilation of individual animal survival, pathology, and summary tables was performed by EG&G Mason Research Institute (5); the statistical analysis was performed by Mr. W. W. Belew (6,7), using methods selected for the Carcinogenesis Testing Program by Dr. J. J. Gart (8). This report was prepared at METREK, a Division of The MITRE Corporation (6) under the direction of the NCI. Those responsible for this report at METREK are the project coordinator, Dr. L. W. Thomas (6), task leader Dr. M. R. Kornreich (6,9), senior biologist Ms. P. Walker (6), biochemist Dr. B. Fuller (6), chemist Dr. N. Zimmerman (6), and technical editor Ms. P. A. Miller (6). The final report was reviewed by members of the participating organizations.

The following other scientists at the National Cancer Institute were responsible for evaluating the bioassay experiment, interpreting the results, and reporting the findings: Dr. K. C. Chu (1), Dr. C. Cueto, Jr. (1), Dr. J. F. Douglas (1), Dr. D. G. Goodman (1,9), Dr. R. A. Griesemer (1), Dr. M. H. Levitt (1), Dr. H. A. Milman (1), Dr. T. W. Orme (1), Dr. R. A. Squire (1,10), Dr. S. F. Stinson (1), Dr. J. M. Ward (1), and Dr. C. E. Whitmire (1).

- 1. Carcinogenesis Testing Program, Division of Cancer Cause and Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
- 2. Now with the Naylor Dana Institute for Disease Prevention, American Health Foundation, Hammon House Road, Valhalla, New York.
- 3. Mason Research Institute, 57 Union Street, Worcester, Massachusetts.
- 4. Tracor Jitco, Inc., 1776 East Jefferson Street, Rockville, Maryland.
- 5. EG&G Mason Research Institute, 1530 East Jefferson Street, Rockville, Maryland.
- 6. The MITRE Corporation, METREK Division, 1820 Dolley Madison Boulevard, McLean, Virginia.
- 7. Now with the Solar Energy Research Institute, Cole Boulevard, Golden, Colorado.
- 8. Mathematical Statistics and Applied Mathematics Section, Biometry Branch, Field Studies and Statistics Program, Division of Cancer Cause and Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
- 9. Now with Clement Associates, Inc., 1010 Wisconsin Avenue, N.W., Washington, D.C.

10. Now with the Division of Comparative Medicine, Johns Hopkins University, School of Medicine, Traylor Building, Baltimore, Maryland.

SUMMARY

A bioassay for possible carcinogenicity of 2,5-toluenediamine sulfate was conducted using Fischer 344 rats and B6C3F1 mice. 2,5-Toluenediamine sulfate was administered in the feed, at either of two concentrations, to groups of 50 males and 50 females of each species. The high and low time-weighted average concentrations of the compound were, respectively, 0.2 and 0.06 percent for rats and 0.1 and 0.06 percent for mice. Because compound administration to the high and low dose groups of each species was not begun simultaneously, each dosed group was assigned a control group. All control groups consisted of 50 animals, except for the high dose male and female rat control groups which were composed of 25 animals. The dosing period was for 78 weeks, followed by an additional 28 to 31 weeks of observation in rats and an additional 16 to 19 weeks in mice.

There was no significant association between compound administration and accelerated mortality in either sex of either species. Adequate numbers of animals in all groups survived sufficiently long to be at risk from late-developing tumors.

A statistically significant incidence of interstitial-cell neoplasms of the testis in dosed male rats was not considered attributable to administration of the compound since the spontaneous incidence of these neoplasms in male Fischer 344 rats is both high and variable. No neoplasms were observed in female rats at statistically significant incidences.

A statistically significant increase in lung tumors in high dose female mice was not considered convincing evidence of a compound-related carcinogenic effect because high dose mice were received in separate shipments from their controls and housed in separate rooms from their controls.

Under the conditions of this bioassay, sufficient evidence was not obtained to demonstrate the carcinogenicity of 2,5-toluenediamine sulfate in either Fischer 344 rats or B6C3Fl mice.

TABLE OF CONTENTS

			Page	
I.	INTRODUCTION			
II.	мат	ERIALS AND METHODS	5	
	B. C. D. E. F. G.	Chemicals Dietary Preparation Animals Animal Maintenance Selection of Initial Concentrations Experimental Design Clinical and Histopathologic Examinations Data Recording and Statistical Analyses	5 6 10 11 15 16	
111.	CHR	ONIC TESTING RESULTS: RATS	21	
		Body Weights and Clinical Observations Survival Pathology Statistical Analyses of Results	21 21 24 25	
IV.	CHR	ONIC TESTING RESULTS: MICE	34	
	A. B. C. D.	Body Weights and Clinical Observations Survival Pathology Statistical Analyses of Results	34 34 37 37	
۷.	DIS	CUSSION	44	
VI.	BIB	LIOGRAPHY	46	
APPEN	DIX	A SUMMARY OF THE INCIDENCE OF NEOPLASMS IN RATS TREATED WITH 2,5-TOLUENEDIAMINE SULFATE	A-1	
APPEN	DIX	B SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MICE TREATED WITH 2,5-TOLUENEDIAMINE SULFATE	B-1	
APPEN	DIX	C SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN RATS TREATED WITH 2,5-TOLUENE- DIAMINE SULFATE	C-1	
APPEN	DIX	D SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MICE TREATED WITH 2,5-TOLUENE- DIAMINE SULFATE	D-1	

LIST OF ILLUSTRATIONS

Figure Number		Page
1	CHEMICAL STRUCTURE OF 2,5-TOLUENEDIAMINE SULFATE	2
2	GROWTH CURVES FOR 2,5-TOLUENEDIAMINE SULFATE CHRONIC STUDY RATS	22
3	SURVIVAL COMPARISONS OF 2,5-TOLUENE- DIAMINE SULFATE CHRONIC STUDY RATS	23
4	GROWTH CURVES FOR 2,5-TOLUENEDIAMINE SULFATE CHRONIC STUDY MICE	35
5	SURVIVAL COMPARISONS OF 2,5-TOLUENE- DIAMINE SULFATE CHRONIC STUDY MICE	36

LIST OF TABLES

Table Number		Page
1	DESIGN SUMMARY FOR FISCHER 344 RATS 2,5-TOLUENEDIAMINE SULFATE FEEDING EXPERIMENT	12
2	DESIGN SUMMARY FOR B6C3F1 MICE 2,5-TOLUENEDIAMINE SULFATE FEEDING EXPERIMENT	13
3	ANALYSES OF THE INCIDENCE OF PRIMARY TUMORS AT SPECIFIC SITES IN MALE RATS TREATED WITH 2,5-TOLUENEDIAMINE SULFATE	26
4	ANALYSES OF THE INCIDENCE OF PRIMARY TUMORS AT SPECIFIC SITES IN FEMALE RATS TREATED WITH 2,5-TOLUENEDIAMINE SULFATE	30
5	ANALYSES OF THE INCIDENCE OF PRIMARY TUMORS AT SPECIFIC SITES IN MALE MICE TREATED WITH 2,5-TOLUENEDIAMINE SULFATE	38
6	ANALYSES OF THE INCIDENCE OF PRIMARY TUMORS AT SPECIFIC SITES IN FEMALE MICE TREATED WITH 2,5-TOLUENEDIAMINE SULFATE	40

LIST OF TABLES (Concluded)

Table Number		Page
A1	SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE RATS TREATED WITH 2,5-TOLUENEDIAMINE SULFATE	A-3
Α2	SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE RATS TREATED WITH 2,5-TOLUENEDIAMINE SULFATE	A-8
B1	SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE MICE TREATED WITH 2,5-TOLUENEDIAMINE SULFATE	B-3
B2	SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE MICE TREATED WITH 2,5-TOLUENEDIAMINE SULFATE	B-6
C1	SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE RATS TREATED WITH 2,5- TOLUENEDIAMINE SULFATE	C-3
C2	SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE RATS TREATED WITH 2,5- TOLUENEDIAMINE SULFATE	C-10
D1	SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE MICE TREATED WITH 2,5- TOLUENEDIAMINE SULFATE	D-3
D 2	SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE MICE TREATED WITH 2,5- TOLUENEDIAMINE SULFATE	D-9

I. INTRODUCTION

2,5-Toluenediamine sulfate (Figure 1) (NCI No. CO1832), a salt of 2,5-toluenediamine and sulfuric acid, was selected for bioassay by the National Cancer Institute in an attempt to determine those dye intermediates which may be responsible for the increased incidence of bladder cancer observed among workers in the dye manufacturing industry (Wynder et al., 1963; Anthony and Thomas, 1970). Aromatic amines are one of several classes of chemicals thought to contribute to the increased cancer risk in this industry (Wynder et al., 1963).

The Chemical Abstracts Service (CAS) Ninth Collective Index (1977) name for this compound is 2-methyl-1,4-benzenediamine sulfate.* It is also called p-tolylenediamine sulfate; p-diaminotoluene sulfate; fouramine standard; and Colour Index (C.I.) oxidation base 4 (C.I. No. 76043).

2,5-Toluenediamine is used in the synthesis of safranine, a family of dyes, some of which are useful as biological stains (Hawley, 1971), and as an oxidation base to dye furs a deep brown (Society of Dyers and Colourists, 1971). In addition, 2,5-toluenediamine is a common component of the "permanent" or oxidative-type hair dye formulations (Ames et al., 1975). It may also be contained in indelible ink, antifreeze, and nail polish. Production statistics for 2,5toluenediamine or its sulfate salt are not available; however, U.S.

The CAS registry number is 6369-59-1.




FIGURE 1 CHEMICAL STRUCTURE OF 2,5-TOLUENEDIAMINE (SULFATE)

imports of this chemical through principal U.S. customs districts amounted to 64,680 pounds in 1974 (U.S. International Trade Commission, 1976).

The potential for exposure to 2,5-toluenediamine is greatest among workers in the dye manufacturing industry, although fur dyers and manufacturers of inks as well as printers, engravers and lithographers may also experience significant daily contact with the chemical. Epidemiological studies suggest a relationship between occupational exposure to printing ink and increased incidence of cancer of both the bladder and the liver (Hoover and Fraumeni, 1975).

Exposure to 2,5-toluenediamine is widespread among the general population due to the increasingly common practice of hair dyeing. It has been estimated that approximately 33 million women in the United States dye their hair, often monthly over a period of many years (Staats, 1977).

2,5-Toluenediamine is toxic following both ingestion and inhalation (Sax, 1975). It can also be absorbed through the skin. Three hours after application of 2,5-toluenediamine to the abdomen of dogs, skin penetration was indicated by blood and urine measurements (Kiese et al., 1968). When applied to the scalp of human volunteers in conjunction with detergents, resorcinol and hydrogen peroxide, the diacetyl derivative was excreted in the urine for two days following application, indicating absorption and metabolism through this route as well (Kiese and Rauscher, 1968). The compound has a toxic action

upon the liver and can cause fatty degeneration of that organ. In addition, it is toxic to the central nervous system and produces anemia by destruction of red blood cells. The compound is considered to be highly irritating, producing irritation and blisters on the fingers of sensitive individuals; permanent injury to an eye was reported following use of 2,5-toluenediamine as an eyelash dye (Sax, 1975).

In studies by Ames et al. (1975), 2,5-toluenediamine was found to cause frameshift mutations in a tester strain (TA 1538) of <u>Salmo-</u> <u>nella typhimurium</u> in the presence of rat liver microsomes. Oxidation of 2,5-toluenediamine by hydrogen peroxide prior to testing resulted in a fortyfold increase in mutagenic activity.

II. MATERIALS AND METHODS

A. Chemicals

2,5-Toluenediamine sulfate was purchased from the Wayland Chemical Division of the Philip A. Hunt Chemical Corporation, Lincoln, Rhode Island. Analysis by the manufacturer suggested a purity of 99 percent with 25 ppm iron, 0.6 percent volatiles, and a maximum of 0.1 percent moisture. Analysis was also performed by Mason Research Institute, Worcester, Massachusetts. The melting point determination showed decomposition above 275°C. No literature value was found for comparison. Thin-layer chromatography utilizing two solvent systems, hexane:benzene:methanol and hexane:ethyl acetate, did not indicate the presence of any impurities. The evidence suggested a compound of high purity.

Throughout this report the term 2,5-toluenediamine sulfate is used to represent this material.

B. Dietary Preparation

The basal laboratory diet for both dosed and control animals consisted of Wayne Lab-Blox[®] (Allied Mills, Inc., Chicago, Illinois). 2,5-Toluenediamine sulfate was administered to the dosed animals as a component of the diet. The chemical was mixed with the feed in a 6 kg capacity Patterson-Kelley standard model stainless steel twin-shell V-blender. After 20 minutes of blending, the mixtures were placed in double plastic bags and stored in the dark at 4°C. Mixtures were prepared weekly and stored for not longer than 2 weeks.

C. Animals

Two animal species, rats and mice, were used in the chronic carcinogenicity bioassay. Fischer 344 rats and B6C3F1 mice were obtained through contracts of the Division of Cancer Treatment, National Cancer Institute. All mice and the high dose rats and their controls were supplied by Charles River Breeding Laboratories, Inc., Wilmington, Massachusetts. The low dose rats and their controls were supplied by Laboratory Supply Co., Inc., Indianapolis, Indiana. Except for the low dose rats and their controls, all the other dosed animals were received in separate shipments from their respective controls.

Upon arrival, a sample of animals was examined for parasites and other signs of disease. The remaining animals were quarantined by species for 2 weeks prior to initiation of test. Animals were assigned to groups and distributed among cages so that the average body weight per cage was approximately equal for a given sex and species.

D. Animal Maintenance

All animals were housed by species in rooms having a temperature range of 23° to 34°C. Incoming air was filtered through Tri-Dek[®] 15/40 denier Dacron[®] filters (Tri-Dim Filter Corp., Hawthorne, New Jersey) providing six changes of room air per hour. Fluorescent lighting was provided on a 12-hour-daily cycle.

Rats were housed five per cage by sex. During quarantine and for the first 13 months of study, low dose rats and their controls

were kept in galvanized- or stainless-steel wire-mesh cages suspended above newspapers. High dose rats and their controls were housed in galvanized-steel wire-mesh cages during quarantine and for the first 11 months of study. Newspapers under cages were replaced daily and cages and racks washed weekly. For the remainder of the study, all rats were housed in suspended polycarbonate cages equipped with disposable nonwoven filter sheets. Clean bedding and cages were provided twice weekly. Low dose rats and their controls received Bed-o-Cobs® corncob bedding (The Andersons Cob Division, Maumee, Ohio) for the first 8 months that they were housed in polycarbonate cages. Thereafter. SAN-I-CEL[®] corncob bedding (Paxton Processing Company, Paxton, Illinois) was used. High dose rats and their controls were provided with SAN-I-CEL[®] for the first 11 months that they were housed in polycarbonate cages, and then Aspen hardwood chip bedding (American Excelsior Company, Baltimore, Maryland) was provided for the remainder of the study. Stainless steel cage racks were cleaned once every 2 weeks and disposable filters were replaced at that time.

Mice were housed by sex in polycarbonate cages. During quarantine and periods of chemical administration, cages were fitted with perforated stainless steel lids. Stainless steel wire bar lids were used during the final observation period. Both types of lids were supplied by Lab Products, Inc., Garfield, New Jersey. Nonwoven fiber filter bonnets were used over cage lids. Low dose mice and their

controls were housed ten per cage for the first 18 months of study and five per cage thereafter. The number of high dose mice per cage was reduced from ten to five after 13 months. The number of high dose controls per cage was reduced to five after 12 months. Clean cages, lids, filters, and bedding were provided three times per week when cage populations were ten and twice per week when cage populations were reduced to five. Bedding was the same as that provided to rats. Ab-sorb-dri[®] (Wilner Wood Products Company, Norway, Maine) hardwood chips were supplied for 2 months to the high dose mice and their controls and for 8 months to the low dose mice and their controls. Both groups received SAN-I-CEL[®] for the next 12 months. Bed-o-Cobs[®] was used until the end of the study. Reusable filter bonnets and pipe racks were sanitized every 2 weeks throughout the study.

Water was available to both species from 250 ml water bottles equipped with rubber stoppers and stainless steel sipper tubes. Bottles were replaced twice weekly and, for rats only, refilled as needed between changes.

Pelleted Wayne Lab-Blox[®] was supplied to all animals during the initial quarantine and final observation periods. During the dosing period, all animals were fed Wayne Lab-Blox[®] meal containing the appropriate concentration of 2,5-toluenediamine sulfate. Control animals had untreated meal available <u>ad libitum</u>. Meal was supplied throughout the study to all mice and to low dose rats and their controls in Alpine[®] aluminum feed cups (Curtin Matheson Scientific, Inc.,

Woburn, Massachusetts) containing stainless steel baffles. High dose rats and their controls were fed from Alpine[®] feed cups for the first 14 months of study and from stainless steel gangstyle hoppers (Scientific Cages, Inc., Bryan, Texas) for the remainder of the study. During the final observation period, mice were fed pellets from a wire bar hopper incorporated into the cage lid, and rats were fed pellets on the cage floor. Food hoppers were changed on the same schedule as were cages. Food was replenished daily in Alpine[®] feed cups.

Dosed rats were housed in a room with other rats receiving diets containing^{*} acetylaminofluorene (53-96-3); a mixture of dulcin (150-69-6) and L-arginine glutamate (4320-30-3); sodium nitrite (7632-00-0); L-arginine glutamate (4320-30-3); N-butylurea (592-31-4); 2-chloro-pphenylenediamine sulfate (61702-44-1); N,N-dimethyl-p-nitrosoaniline (138-89-6); 2,4-dinitrotoluene (121-14-2); 4-nitroanthranilic acid (619-17-0); 1,5-naphthalenediamine (2243-62-1); N-(1-naphthyl)ethylenediamine dihydrochloride (1465-25-4); and aniline hydrochloride (142-04-1). Control rats were housed in a room with other rats receiving diets containing 1-nitronaphthalene (86-57-7); 5-nitro-o-toluidine (99-55-8); hydrazobenzene (530-50-7); 2-aminoanthraquinone (117-79-3); 6-nitrobenzimidazole (94-52-0); 3-amino-9-ethylcarbazole hydrochloride; 2,4-diaminoanisole sulfate (615-05-4); and APC (8003-03-0).

CAS registry numbers are given in parentheses.

High dose mice shared a room with other mice receiving diets containing 5-nitro-o-toluidine (99-55-8); hydrazobenzene (530-50-7); 3-amino-9-ethylcarbazole hydrochloride; 1-nitronaphthalene (86-57-7); 6-nitrobenzimidazole (94-52-0); 5-nitro-o-anisidine (99-59-2); and 2,4-diaminoanisole sulfate (615-05-4). High dose control mice were housed in a room with other mice receiving diets containing 2-methyl-1-nitroanthraquinone (129-15-7); 4-chloro-m-phenylenediamine (5131-60-2); acetylaminofluorene (53-96-3); p-cresidine (120-71-8); and fenaminosulf (140-56-7). Low dose mice and their controls were in a room with other mice receiving diets containing amitrole (61-82-5); APC (8003-03-0); N,N-dimethyl-p-nitrosoaniline (138-89-6); 2,4-dinitrotoluene (121-14-2); 4-nitroanthranilic acid (619-17-0); 2-aminoanthraquinone (117-79-3); 3-amino-4-ethoxyacetanilide (17026-81-2); 3-amino-9-ethylcarbazole hydrochloride; 1-amino-2-methylanthraquinone (82-28-0); 5-nitro-o-anisidine (99-59-2); 1-nitronaphthalene (86-57-7); 5-nitroacenaphthene (602-87-9); 3-nitro-p-acetophenetide (1777-84-0); and 2,4-diaminoanisole sulfate (615-05-4).

E. Selection of Initial Concentrations

In order to establish the maximum tolerated concentrations of 2,5-toluenediamine sulfate for administration to dosed animals in the chronic studies, subchronic toxicity tests were conducted with both Fischer 344 rats and C57BL/6 mice.^{*} Rats and mice were distributed among five groups, each consisting of five males and five

This strain was used due to the unavailability at that time of B6C3F1 mice.

females. 2,5-Toluenediamine sulfate was incorporated into the basal laboratory diet and fed <u>ad libitum</u> to four of the five rat groups and four of the five mouse groups in concentrations of 0.02, 0.05, 0.08, and 0.11 percent. The remaining group of each species served as control groups, receiving only the basal laboratory diet. The dosed dietary preparations were administered for a period of 4 weeks, followed by 2 weeks of observation.

All animals survived until necropsy. Mean body weight depression relative to controls was observed in all dosed rat groups and in dosed female mice; however, the depression was not dose-related. No mean body weight depression was observed in male mice.

The high concentrations selected for administration in the chronic study were 0.05 percent for rats and 0.06 percent for mice.

F. Experimental Design

The experimental design parameters for the chronic study (species, sex, group size, actual concentrations administered, duration of treated and untreated observation periods, and time-weighted average concentrations) are summarized in Tables 1 and 2.

At initiation of the study, all animals were approximately 6 weeks old. High dose rats and their controls were placed on test 11 months after low dose rats and their controls. Each dosed rat group was placed on test during the same week as its respective control group. Rats initially received 2,5-toluenediamine sulfate at dietary concentrations of 0.05 and 0.03 percent. Because of a lack

TABLE 1

٠

DESIGN SUMMARY FOR FISCHER 344 RATS 2,5-TOLUENEDIAMINE SULFATE FEEDING EXPERIMENT

	INITIAL GROUP SIZE	2,5-TOLUENEDIAMINE SULFATE CONCENTRATION (PERCENT)	OBSERVAT TREATED (WEEKS)	ION PERIOD UNTREATED (WEEKS)	TIME-WEIGHTED AVERAGE CONCENTRATION ^a
MALE					
LOW DOSE CONTROL	50	0	0	107	0
HIGH DOSE CONTROL	L 25	0	0	109	0
LOW DOSE	50	0.05 0.06 0	14 64	28	0.06
HIGH DOSE	50	0.2 0	78	30	0.2
FEMALE					
LOW DOSE CONTROL	50	0	0	108	0
HIGH DOSE CONTROL	25	0	0	109	0
LOW DOSE	50	0.05 0.06 0	14 64	29	0.06
HIGH DOSE	50	0.2 0	78	31	0.2

^aTime-weighted average concentration = $\frac{\Sigma(\text{concentration X weeks received})}{\Sigma(\text{weeks receiving chemical})}$

TABLE 2

DESIGN SUMMARY FOR B6C3F1 MICE 2,5-TOLUENEDIAMINE SULFATE FEEDING EXPERIMENT

	INITIAL GROUP SIZE	2,5-TOLUENEDIAMINE SULFATE CONCENTRATION (PERCENT)	OBSERVAT TREATED (WEEKS)	ION PERIOD UNTREATED (WEEKS)
MALE				
LOW DOSE CONTROL	50	0	0	96
HIGH DOSE CONTROL	50	0	0	98
LOW DOSE	50	0.06 0	78	16
HIGH DOSE	50	0.1 0	78	19
FEMALE	<u></u>			
LOW DOSE CONTROL	50	0	0	97
HIGH DOSE CONTROL	50	0	0	98
LOW DOSE	50	0.06 0	78	16
HIGH DOSE	50	0.1 0	78	19

,

of observed mean body weight depression or other clinical signs at a level of 0.05 percent, the groups receiving 0.03 percent were terminated 2 months after initiation, and a new group was initiated at a concentration of 0.2 percent along with a new control group. Throughout this report those rats receiving a concentration of 0.2 percent and their controls are referred to as the high dose and high dose control groups, respectively, while those rats initially receiving a concentration of 0.05 percent and their controls are referred to as the low dose and low dose control groups, respectively. From week 15, the concentration received by the low dose group was increased from 0.05 to 0.06 percent.

Low dose mice were placed on test 6 months before high dose mice. Low dose mice were placed on test 2 weeks before their controls. High dose mice were placed on test 2 months after their controls. The initial dietary concentrations utilized for mice were 0.06 and 0.03 percent. Again, because of a lack of observed mean body weight depression or other clinical signs, the group receiving 0.03 percent was discontinued 6 months after initiation and a new group was initiated at a concentration of 0.1 percent, accompanied by a new control group. Throughout this report those mice receiving a concentration of 0.1 percent and their controls are referred to as the high dose and high dose control groups, respectively, while those mice receiving a concentration of 0.06 percent and their controls are referred to as the low dose and low dose control groups, respectively.

G. Clinical and Histopathologic Examinations

Animals were weighed immediately prior to initiation of the experiment. Body weights were recorded twice weekly for the first 12 weeks of the study and at monthly intervals thereafter. Food consumption, for two cages from each group, was monitored for seven consecutive days once a month for the first nine months of the bioassay and for three consecutive days each month thereafter. The presence of tissue masses and lesions was determined by monthly observation and palpation of each animal. From the first day, all animals were inspected twice daily for mortality.

A necropsy was performed on each animal regardless of whether it died, was killed when moribund, or was sacrificed at the end of the bioassay. The animals were euthanized by carbon dioxide inhalation, and were immediately necropsied. The histopathologic examination consisted of gross and microscopic examination of major tissues, organs, and gross lesions taken from sacrificed animals and, whenever possible, from animals found dead.

Tissues were preserved in 10 percent buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin prior to microscopic examination. An occasional section was subjected to special staining techniques for more definitive diagnosis.

Slides were prepared from the following tissues: skin, subcutaneous tissue, lungs and bronchi, trachea, bone marrow, spleen, lymph

nodes, thymus, heart, salivary gland, liver, gallbladder (mice), pancreas, esophagus, stomach, small intestine, large intestine, kidney, urinary bladder, pituitary, adrenal, thyroid, parathyroid, testis, prostate, seminal vesicle, brain, tunica vaginalis, muscle, ear, uterus, mammary gland, and ovary.

A few tissues were not examined for some animals, particularly for those that died early. Also, some animals were missing, cannibalized, or judged to be in such an advanced state of autolysis as to preclude histopathologic interpretation. Thus, the number of animals for which particular organs, tissues, or lesions were examined microscopically varies and does not necessarily represent the number of animals that were placed on experiment in each group.

H. Data Recording and Statistical Analyses

Pertinent data on this experiment have been recorded in an automatic data processing system, the Carcinogenesis Bioassay Data System (Linhart et al., 1974). The data elements include descriptive information on the chemicals, animals, experimental design, clinical observations, survival, body weight, and individual pathologic results, as recommended by the International Union Against Cancer (Berenblum, 1969). Data tables were generated for verification of data transcription and for statistical review.

These data were analyzed using the statistical techniques described in this section. Those analyses of the experimental results that bear on the possibility of carcinogenicity are discussed in the statistical narrative sections.

Probabilities of survival were estimated by the product-limit procedure of Kaplan and Meier (1958) and are presented in this report in the form of graphs. Animals were statistically censored as of the time that they died of other than natural causes or were found to be missing; animals dying from natural causes were not statistically censored. Statistical analyses for a possible dose-related effect on survival used the method of Cox (1972) when testing two groups for equality and used Tarone's (1975) extensions of Cox's methods when testing a dose-related trend. One-tailed P-values have been reported for all tests except the departure from linearity test, which is only reported when its two-tailed P-value is less than 0.05.

The incidence of neoplastic or nonneoplastic lesions has been given as the ratio of the number of animals bearing such lesions at a specific anatomic site (numerator) to the number of animals in which that site was examined (denominator). In most instances, the denominators included only those animals for which that site was examined histologically. However, when macroscopic examination was required to detect lesions prior to histologic sampling (e.g., skin or mammary tumors), or when lesions could have appeared at multiple sites (e.g., lymphomas), the denominators consist of the numbers of animals necropsied.

The purpose of the statistical analyses of tumor incidence is to determine whether animals receiving the test chemical developed a significantly higher proportion of tumors than did the control animals.

As a part of these analyses, the one-tailed Fisher exact test (Cox, 1970, pp. 48-52) was used to compare the tumor incidence of a control group to that of a group of treated animals at each dose level. When results for a number of treated groups, k, are compared simultaneously with those for a control group, a correction to ensure an overall significance level of 0.05 may be made. The Bonferroni inequality (Miller, 1966, pp. 6-10) requires that the P-value for any comparison be less than or equal to 0.05/k. In cases where this correction was used, it is discussed in the narrative section. It is not, however, presented in the tables, where the Fisher exact P-values are shown.

The Cochran-Armitage test for linear trend in proportions, with continuity correction (Armitage, 1971, pp. 362-365), was also used when appropriate. Under the assumption of a linear trend, this test determined if the slope of the dose-response curve is different from zero at the one-tailed 0.05 level of significance. Unless otherwise noted, the direction of the significant trend was a positive dose relationship. This method also provides a two-tailed test of departure from linear trend.

A time-adjusted analysis was applied when numerous early deaths resulted from causes that were not associated with the formation of tumors. In this analysis, deaths that occurred before the first tumor was observed were excluded by basing the statistical tests on animals that survived at least 52 weeks, unless a tumor was found at the anatomic site of interest before week 52. When such an early

tumor was found, comparisons were based exclusively on animals that survived at least as long as the animal in which the first tumor was found. Once this reduced set of data was obtained, the standard procedures for analyses of the incidence of tumors (Fisher exact tests, Cochran-Armitage tests, etc.) were followed.

When appropriate, life-table methods were used to analyze the incidence of tumors. Curves of the proportions surviving without an observed tumor were computed as in Saffiotti et al. (1972). The week during which animals died naturally or were sacrificed was entered as the time point of tumor observation. Cox's methods of comparing these curves were used for two groups; Tarone's extension to testing for linear trend was used for three groups. The statistical tests for the incidence of tumors which used life-table methods were one-tailed and, unless otherwise noted, in the direction of a positive dose relationship. Significant departures from linearity (P < 0.05, two-tailed test) were also noted.

The approximate 95 percent confidence interval for the relative risk of each dosed group compared to its control was calculated from the exact interval on the odds ratio (Gart, 1971). The relative risk is defined as p_t/p_c where p_t is the true binomial probability of the incidence of a specific type of tumor in a treated group of animals and p_c is the true probability of the spontaneous incidence of the same type of tumor in a control group. The hypothesis of equality between the true proportion of a specific tumor in a treated group

and the proportion in a control group corresponds to a relative risk of unity. Values in excess of unity represent the condition of a larger proportion in the treated group than in the control.

The lower and upper limits of the confidence interval of the relative risk have been included in the tables of statistical analy-The interpretation of the limits is that in approximately 95 ses. percent of a large number of identical experiments, the true ratio of the risk in a treated group of animals to that in a control group would be within the interval calculated from the experiment. When the lower limit of the confidence interval is greater than one, it can be inferred that a statistically significant result (a P < 0.025one-tailed test when the control incidence is not zero, P < 0.050when the control incidence is zero) has occurred. When the lower limit is less than unity but the upper limit is greater than unity, the lower limit indicates the absence of a significant result while the upper limit indicates that there is a theoretical possibility of the induction of tumors by the test chemical which could not be detected under the conditions of this test.

III. CHRONIC TESTING RESULTS: RATS

A. Body Weights and Clinical Observations

When compared to their respective controls, the high dose female rats exhibited consistent mean body weight depression. This trend was not as evident in the other groups of dosed rats (Figure 2).

Only isolated clinical observations were reported. These included crusted lesions on the dorsolateral surface in one low dose control male and one low dose male and on the side of the head in one low dose female; tissue masses on the ear in two low dose males and on the foreleg in one low dose male; a subcutaneous mass under the base of the tail in one high dose male; and growths on the foreleg in three low dose females and on the ear in another low dose female.

B. Survival

The estimated probabilities of survival for male and female rats in the control and 2,5-toluenediamine sulfate-dosed groups are shown in Figure 3. For both male and female rats there was no significant association between dosage and mortality.

There were adequate numbers of male rats at risk from latedeveloping tumors despite the sacrifice in week 78 of five rats from the low dose and each control group, and the sacrifice in week 29 of ten additional rats from the low dose control group. Five males from the high dose group died in week 78. Ninety percent (45/50) of the high dose, 84 percent (42/50) of the low dose, 72 percent (18/25) of




FIGURE 2 GROWTH CURVES FOR 2,5-TOLUENEDIAMINE SULFATE CHRONIC STUDY RATS




FIGURE 3 SURVIVAL COMPARISONS OF 2,5-TOLUENEDIAMINE SULFATE CHRONIC STUDY RATS

the high dose control, and 58 percent (29/50) of the low dose control group survived on test at least 85 weeks.

There were adequate numbers of female rats at risk from latedeveloping tumors despite the sacrifice in week 78 of five rats from the low dose and each control group and the sacrifice in week 29 of ten additional rats from the low dose control group. Five of the high dose females died in week 78. Eighty-six percent (43/50) of the high dose, 84 percent (42/50) of the low dose, 68 percent (17/25) of the high dose control, and 66 percent (33/50) of the low dose control group survived on test at least 85 weeks.

C. Pathology

Histopathologic findings on neoplasms in rats are summarized in Appendix A (Tables Al and A2); findings on nonneoplastic lesions are summarized in Appendix C (Tables Cl and C2).

A variety of neoplasms which are routinely seen in this strain of rat was recorded. The incidences of these tumors in dosed rats were not judged to be attributable to the administration of 2,5-toluenediamine sulfate.

Nonneoplastic lesions which commonly occur in aging Fischer 344 rats and which were unrelated to the administration of the test compound were seen.

This pathologic examination provided no evidence for the carcinogenicity of 2,5-toluenediamine sulfate in Fischer 344 rats.

D. Statistical Analyses of Results

The results of the statistical analyses of tumor incidence in rats are summarized in Tables 3 and 4. The analysis for every type of tumor that was observed in more than 5 percent of any of the 2,5toluenediamine sulfate-dosed groups of either sex is included. In addition to these analyses, time-adjusted analyses were performed based upon animals surviving at least 52 weeks; the time-adjusted analyses did not produce different conclusions from the analyses presented here.

In male rats, the Fisher exact test indicated a significant incidence of interstitial-cell tumors of the testis when the high dose group was compared to the high dose control (P = 0.014). The comparison of low dose to low dose control had a probability level of P = 0.039, which was not significant under the Bonferroni criterion. These results were discounted, however, due to the well-known high variation in the spontaneous incidence of this tumor (Cockrell and Garner, 1976).

For females the Fisher exact test indicated a significantly (P = 0.006) lower incidence of pituitary adenomas in the low dose group than in the low dose control group. The high dose comparison was not significant.

No other test for any site in either male or female rats was significant under the Bonferroni criterion. Based upon these statistical results there was no convincing evidence of the carcinogenicity of 2,5-toluenediamine sulfate in rats.

TABLE 3

ANALYSES OF THE INCIDENCE OF PRIMARY TUMORS AT SPECIFIC SITES IN MALE RATS TREATED WITH 2,5-TOLUENEDIAMINE SULFATE^a

TOPOGRAPHY: MORPHOLOGY	LOW DOSE CONTROL	HIGH DOSE CONTROL	LOW DOSE	HIGH DOSE
	CONTROL	CONTROL	D03E	DOSE
Lung: Alveolar/Bronchiolar Adenoma or Alveolar/Bronchiolar Carcinoma ^b	0/46(0.00)	3/25(0.12)	1/48(0.02)	0/49(0.00)
P Values ^C			N.S.	P = 0.035(N)
Relative Risk (Control) ^d			Infinite	0.000
Lower Limit			0.051	0.000
Upper Limit	anat diffi yan		Infinite	0.843
Weeks to First Observed Tumor		78	97	
Hematopoietic System: Leukemia or	<u> </u>	,		
Malignant Lymphoma ^b	2/46(0.04)	4/25(0.16)	5/49(0.10)	8/49(0.16)
P Values ^C			N.S.	N.S.
Relative Risk (Control) ^d			2.347	1.020
Lower Limit			0.407	0.310
Upper Limit			23.709	4.278
Weeks to First Observed Tumor	79	85	89	99
Pituitary: Adenoma NOS, Basophil	······································	······································		
Adenoma or Chromophobe Adenomab	12/41(0.29)	3/21(0.14)	3/45(0.07)	3/40(0.08)
P Values ^C			P = 0.006(N)	N.S.
Relative Risk (Control) ^d			0.228	0.525
Lower Limit			0.044	0.078
Upper Limit			0.772	3.650
Weeks to First Observed Tumor	101	78	106	108

TABLE	3	(CONTINUED)
	9	(CONTINUED)

TOPOGRAPHY : MORPHOLOGY	LOW DOSE CONTROL	HIGH DOSE CONTROL	LOW DOSE	HIGH DOSE
IOFOGRAFHI: MORFHOLOGI	CONTROL	CONTROL	DO2F	DOSE
Adrenal: Pheochromocytoma or Pheochromocytoma Malignant ^b	6/43(0.14)	4/25(0.16)	2/48(0.04)	1/48(0.02)
P Values ^C			N.S.	P = 0.044(N)
Relative Risk (Control) ^d Lower Limit			0.299 0.031 1.568	0.130 0.003 1.237
Upper Limit				
Weeks to First Observed Tumor	107	68	103	108
Thyroid: Papillary Adenocarcinoma ^b	0/45(0.00)	0/23(0.00)	3/46(0.07)	0/47(0.00)
P Values ^C			N.S.	
Relative Risk (Control) ^d			Infinite	
Lower Limit			0.590	
Upper Limit			Infinite	
Weeks to First Observed Tumor			106	
Thyroid: Adenocarcinoma NOS, Papillary Adenocarcinoma, Cyst- adenocarcinoma NOS, or Papillary Cystadenocarcinoma NOS ^b	2/45(0.04)	0/23(0.00)	3/46(0.07)	3/47(0.06)
P Values ^C			N.S.	N.S.
Relative Risk (Control) ^d			1.467	Infinite
Lower Limit			0.176	0.303
Upper Limit			16.894	Infinite
Weeks to First Observed Tumor	107		106	105

	LOW DOSE	HIGH DOSE	LOW	HIGH
TOPOGRAPHY : MORPHOLOGY	CONTROL	CONTROL	DOSE	DOSE
Pancreatic Islets: Islet-Cell Adenoma ^b	2/42(0.05)	2/25(0.08)	4/48(0.08)	1/48(0.02)
P Values ^C			N.S.	N.S.
Relative Risk (Control) ^d Lower Limit Upper Limit			1.750 0.266 18.600	0.260 0.005 4.803
Weeks to First Observed Tumor	107	109	106	108
Preputial Gland: Adenoma NOS or Carcinoma NOS ^b	0/46(0.00)	2/25(0.08)	0/49(0.00)	2/49(0.04)
P Values ^C			N.S.	N.S.
Relative Risk (Control) ^d Lower Limit Upper Limit				0.510 0.040 6.750
Weeks to First Observed Tumor		85		108
Testis: Interstitial-Cell Tumor ^b	33/45(0.73)	19/24(0.79)	43/48(0.90)	47/48(0.98)
P Values ^C			P = 0.039	P = 0.014
Relative Risk (Control) ^d Lower Limit Upper Limit			1.222 0.981 1.446	1.237 1.017 1.331
Weeks to First Observed Tumor	78	78	78	78

TABLE 3 (CONTINUED)

TABLE 3 (CONCLUDED)

^aTreated groups received time-weighted average doses of 0.06 or 0.20 percent in feed.

^bNumber of tumor-bearing animals/number of animals examined at site (proportion).

^CThe probability level for the Fisher exact test for the comparison of a treated group with its control group is given beneath the incidence of tumors in the treated group when P < 0.05; otherwise, not significant (N.S.) is indicated. A negative designation (N) indicates a lower incidence in the treated group than in the control group.

 $^{\rm d}$ The 95% confidence interval on the relative risk of the treated group to the control group.

TABLE 4

ANALYSES OF THE INCIDENCE OF PRIMARY TUMORS AT SPECIFIC SITES IN FEMALE RATS TREATED WITH 2,5-TOLUENEDIAMINE SULFATE^a

	LOW DOSE	HIGH DOSE	LOW	HIGH
TOPOGRAPHY: MORPHOLOGY	CONTROL	CONTROL	DOSE	DOSE
Hematopoietic System: Leukemia or Malignant Lymphoma ^b	4/49(0.08)	2/23(0.09)	2/50(0.04)	10/50(0.20)
P Values ^C		 	N.S.	N.S.
Relative Risk (Control) ^d			0.490	2.300
Lower Limit			0.046	0.553
Upper Limit			3.251	20.530
Weeks to First Observed Tumor	101	106	107	81
Pituitary: Adenoma NOS or Chromo-				
phobe Adenoma ^b	18/43(0.42)	8/21(0.38)	17/48(0.35)	10/43(0.23)
P Values ^C			N.S.	N.S.
Relative Risk (Control) ^d			0.846	0.611
Lower Limit	****		0.477	0.266
Upper Limit			1.507	1.546
Weeks to First Observed Tumor	76	78	80	108
Adrenal: Pheochromocytoma or				
Pheochromocytoma Malignant ^D	2/46(0.04)	3/23(0.13)	1/50(0.02)	1/48(0.02)
P Values ^C			N.S.	N.S.
Relative Risk (Control) ^d			0.460	0.160
Lower Limit	~~~		0.008	0.003
Upper Limit			8.542	1.882
Weeks to First Observed Tumor	108	109	107	109

	LOW DOSE	HIGH DOSE	LOW	HIGH
TOPOGRAPHY: MORPHOLOGY	CONTROL	CONTROL	DOSE	DOSE
Thyroid: C-Cell Adenoma or C-Cell Carcinoma ^b	1/47(0.02)	3/21(0.14)	3/48(0.06)	0/49(0.00)
P Values ^c			N.S.	P = 0.025(N)
Relative Risk (Control) ^d Lower Limit Upper Limit			2.938 0.246 150.900	0.000 0.000 0.707
Weeks to First Observed Tumor	107	109	107	
Mammary Gland: Adenocarcinoma NOS, Papillary Adenocarcinoma, Papillary Cystadenocarcinoma NOS or In-		2/22/0 12)	1/50/0 00	1/50/0 00
filtrating Duct Carcinoma ^D	2/49(0.04)	3/23(0.13)	1/50(0.02)	1/50(0.02)
P Values ^C			N.S.	N.S.
Relative Risk (Control) ^d			0.490	0.153
Lower Limit			0.008	0.003
Upper Limit			9.103	1.810
Weeks to First Observed Tumor	101	52	107	108
Mammary Gland: Fibroadenoma ^b	4/49(0.08)	4/23(0.17)	6/50(0.12)	9/50(0.18)
P Values ^C			N.S.	N.S.
Relative Risk (Control) ^d			1.470	1.035
Lower Limit			0.372	0.332
Upper Limit	titur sina titur		6.681	4.234
Weeks to First Observed Tumor	101	109	100	108

TABLE 4 (CONCLUDED)

TOPOGRAPHY: MORPHOLOGY	LOW DOSE CONTROL	HIGH DOSE CONTROL	LOW DOSE	HIGH DOSE
Uterus: Endometrial Stromal Polyp ^b	10/48(0.21)	6/23(0.26)	7/49(0.14)	7/45(0.16)
P Values ^C			N.S.	N.S.
Relative Risk (Control) ^d Lower Limit Upper Limit	 		0.686 0.241 1.826	0.596 0.199 1.932
Weeks to First Observed Tumor	78	87	101	108
Uterus: Adenocarcinoma NOS ^b	4/48(0.08)	0/23(0.00)	3/49(0.06)	1/45(0.02)
P Values ^C			N.S.	N.S.
Relative Risk (Control) ^d Lower Limit Upper Limit			0.735 0.113 4.114	Infinite 0.028 Infinite
Weeks to First Observed Tumor	95		92	109

^aTreated groups received time-weighted average doses of 0.06 or 0.20 percent in feed.

^bNumber of tumor-bearing animals/number of animals examined at site (proportion).

^CThe probability level for the Fisher exact test for the comparison of a treated group with its control group is given beneath the incidence of tumors in the treated group when P < 0.05; otherwise, not significant (N.S.) is indicated. A negative designation (N) indicates a lower incidence in the treated group than in the control group.

 d The 95% confidence interval on the relative risk of the treated group to the control group.

To provide additional insight into the possible carcinogenicity of this compound, 95 percent confidence intervals on the relative risk have been estimated and entered in the tables based upon the observed tumor incidence rates. In many of the intervals shown in Tables 3 and 4, the value one is included; this indicates the absence of statistically significant results. It should also be noted that many of the confidence intervals have an upper limit greater than one, indicating the theoretical possibility of tumor induction in rats by 2,5-toluenediamine sulfate that could not be established under the conditions of this test.

IV. CHRONIC TESTING RESULTS: MICE

A. Body Weights and Clinical Observations


The only group exhibiting distinct compound-related mean body weight depression when compared to its control group was the high dose female group (Figure 4). It should be noted, however, that the growth pattern of the female high dose control group was unusual (i.e., it did not level off as the animals approached maturity).

No clinical abnormalities were recorded for dosed or control mice of either sex.

B. Survival

The estimated probabilities of survival for male and female mice in the control and 2,5-toluenediamine sulfate-dosed groups are shown in Figure 5. There was no significant association between dosage and mortality for male or female mice.

Five male and five female mice were sacrificed in week 78 from each group except the low dose group. There were adequate numbers of male mice at risk from late-developing tumors as 74 percent (37/50) of the high dose, 94 percent (47/50) of the low dose, 74 percent (37/50) of the high dose control, and 84 percent (42/50) of the low dose control mice survived on test until the end of the study. There were also adequate numbers of female mice at risk from late-developing tumors as 66 percent (33/50) of the high dose, 78 percent (39/50) of the low dose, 70 percent (35/50) of the high dose control, and 74








FIGURE 5 SURVIVAL COMPARISONS OF 2,5-TOLUENEDIAMINE SULFATE CHRONIC STUDY MICE

percent (37/50) of the low dose control mice survived on test until the end of the study.

C. Pathology

Histopathologic findings on neoplasms in mice are summarized in Appendix B (Tables B1 and B2); findings on nonneoplastic lesions are summarized in Appendix D (Tables D1 and D2).

Hepatocellular carcinoma occurred in 7/48 (15 percent) of the low dose control males, 10/45 (22 percent) of the high dose control males, 8/48 (17 percent) of the low dose males, and 16/49 (33 percent) of the high dose males. None of the tumors was judged to be due to the administration of the test chemical.

A variety of inflammatory and degenerative lesions which commonly occur in aging mice of this strain was seen. These nonneoplastic lesions were not considered to be compound-related.

This pathologic examination provided no evidence for the carcinogenicity of 2,5-toluenediamine sulfate in B6C3F1 mice.

D. Statistical Analyses of Results

The results of the statistical analyses of tumor incidence in mice are summarized in Tables 5 and 6. The analysis for every type of tumor that was observed in more than 5 percent of any of the 2,5-toluenediamine sulfate-dosed groups of either sex is included.

Elevated incidences of alveolar/bronchiolar adenomas and alveolar/ bronchiolar carcinomas were observed among dosed female mice. For

TABLE 5

ANALYSES OF THE INCIDENCE OF PRIMARY TUMORS AT SPECIFIC SITES IN MALE MICE TREATED WITH 2,5-TOLUENEDIAMINE SULFATE^a

	LOW DOSE	HIGH DOSE	LOW	HIGH
TOPOGRAPHY: MORPHOLOGY	CONTROL	CONTROL	DOSE	DOSE
Lung: Alveolar/Bronchiolar Carcinoma ^b	6/48(0.13)	4/45(0.09)	1/47(0.02)	5/49(0.10)
P Values ^C			N.S.	N.S.
Relative Risk (Control) ^d Lower Limit			0.170 0.004	1.148 0.264
Upper Limit			1.326	5.453
Weeks to First Observed Tumor	96	97	94	96
Lung: Alveolar/Bronchiolar Car- cinoma or Alveolar/Bronchiolar				
Adenoma ^b	6/48(0.13)	11/45(0.24)	6/47(0.13)	10/49(0.20)
P Values ^C			N.S.	N.S.
Relative Risk (Control) ^d			1.021	0.835
Lower Limit			0.294 3.548	0.353 1.955
Upper Limit				
Weeks to First Observed Tumor	96	78	94	96
Hematopoietic System: Leukemia or Malignant Lymphoma ^b	4/48(0.08)	2/46(0.04)	5/49(0.10)	4/49(0.08)
P Values ^C			N.S.	N.S.
Relative Risk (Control) ^d			1.224	1.878
Lower Limit	~~~		0.281	0.284
Upper Limit			5.823	19.990
Weeks to First Observed Tumor	96	97	94	72

TABLE 5 (CONCLUDED)

TOPOGRAPHY: MORPHOLOGY	LOW DOSE CONTROL	HIGH DOSE CONTROL	LOW DOSE	HIGH DOSE
Liver: Hepatocellular Carcinoma	7/48(0.15)	10/45(0.22)	8/48(0.17)	16/49(0.33)
P Values ^C			N.S.	N.S.
Relative Risk (Control) ^d Lower Limit Upper Limit			1.143 0.394 3.411	1.469 0.705 3.233
Weeks to First Observed Tumor	78	93	94	77
Liver: Hepatocellular Carcinoma or Neoplastic Nodule ^b	7/48(0.15)	10/45(0.22)	8/48(0.17)	18/49(0.37)
P Values ^C			N.S.	N.S.
Relative Risk (Control) ^d Lower Limit Upper Limit			1.143 0.394 3.411	1.653 0.817 3.558
Weeks to First Observed Tumor	78	93	94	77

^aTreated groups received doses of 0.06 or 0.10 percent in feed.

^bNumber of tumor-bearing animals/number of animals examined at site (proportion).

^CThe probability level for the Fisher exact test for the comparison of a treated group with its control group is given beneath the incidence of tumors in the treated group when P < 0.05; otherwise, not significant (N.S.) is indicated. A negative designation (N) indicates a lower incidence in the treated group than in the control group.

 d The 95% confidence interval on the relative risk of the treated group to the control group.

TABLE 6

ANALYSES OF THE INCIDENCE OF PRIMARY TUMORS AT SPECIFIC SITES IN FEMALE MICE TREATED WITH 2,5-TOLUENEDIAMINE SULFATE^a

TOPOGRAPHY: MORPHOLOGY	LOW DOSE	HIGH DOSE	LOW	HIGH
IUPUGKAPHI: NUKPHULUGI	CONTROL	CONTROL	DOSE	DOSE
Lung: Alveolar/Bronchiolar Adenoma or Alveolar/Bronchiolar Carcinoma ^b	4/46(0.09)	1/45(0.02)	6/42(0.14)	8/45(0.17)
P Values ^C			N.S.	P = 0.016
Relative Risk (Control) ^d			1.643	7.826
Lower Limit			0.419	1.118
Upper Limit			7.390	338.408
Weeks to First Observed Tumor	96	98	94	78
Hematopoietic System: Leukemia or Malignant Lymphoma ^b	5/48(0.10)	12/46(0.26)	4/45(0.09)	8/47(0.17)
P Values ^C			N.S.	N.S.
Relative Risk (Control) ^d			0.853	0.653
Lower Limit			0.180	0.256
Upper Limit			3.711	1.568
Weeks to First Observed Tumor	96	95	94	78
Liver: Hepatocellular Carcinoma ^b	1/47(0.02)	4/45(0.09)	2/42(0.05)	4/46(0.09)
P Values ^C			N.S.	N.S.
Relative Risk (Control) ^d			2.238	1.000
Lower Limit			0.121	0.198
Upper Limit			128,900	5.050
Weeks to First Observed Tumor	96	78	93	94

TABLE 6 (CONCLUDED)

TOPOGRAPHY : MORPHOLOGY	LOW DOSE CONTROL	HIGH DOSE CONTROL	LOW DOSE	HIGH DOSE
Pituitary: Adenoma NOS or Car- cinoma NOS ^b	3/42(0.07)	6/37(0.16)	1/38(0.03)	0/38(0.00)
P Values ^C			N.S.	P = 0.012(N)
Relative Risk (Control) ^d Lower Limit Upper Limit			0.368 0.007 4.349	0.000 0.000 0.602
Weeks to First Observed Tumor	96	98	94	
Ovary: Papillary Cystadenoma NOS or Tubular Adenoma ^b	1/45(0.02)	0/41(0.00)	0/36(0.00)	2/39(0.05)
P Values ^C			N.S.	N.S.
Relative Risk (Control) ^d Lower Limit Upper Limit			0.000 0.000 23.152	Infinite 0.313 Infinite
Weeks to First Observed Tumor	78			97

^aTreated groups received doses of 0.06 or 0.10 percent in feed.

^bNumber of tumor-bearing animals/number of animals examined at site (proportion).

^CThe probability level for the Fisher exact test for the comparison of a treated group with its control group is given beneath the incidence of tumors in the treated group when P < 0.05; otherwise, not significant (N.S.) is indicated. A negative designation (N) indicates a lower incidence in the treated group than in the control group.

 $^{
m d}$ The 95% confidence interval on the relative risk of the treated group to the control group.

the combined incidence in females, the Fisher exact test comparing high dose to high dose control was significant (P = 0.016). In historical data collected by this laboratory for the NCI Carcinogenesis Testing Program 12/350 (3 percent) of the untreated B6C3F1 female mice had an alveolar/bronchiolar adenoma, alveolar/bronchiolar carcinoma, alveolar-cell adenocarcinoma, or an adenoma NOS of the lung/alveoli--compared to the 4/46 (9 percent), 1/45 (2 percent), 6/42 (14 percent), and 8/45 (17 percent) observed in the low dose control, high dose control, low dose, and high dose groups, respectively, in this bioassay.

Based upon these results the statistical conclusion is that the administration of 2,5-toluenediamine sulfate was associated with the incidence of alveolar/bronchiolar neoplasms in female B6C3F1 mice.

For females the Fisher exact test indicated a significantly (P = 0.012) lower combined incidence of pituitary adenomas NOS or pituitary carcinomas NOS in the high dose group than in the high dose control. The low dose comparison was not significant.

To provide additional insight into the possible carcinogenicity of this compound, 95 percent confidence intervals on the relative risk have been estimated and entered in the tables based upon the observed tumor incidence rates. In many of the intervals shown in Tables 5 and 6, the value one is included; this indicates the absence of statistically significant results. It should also be noted that many of the confidence intervals have an upper limit greater than

one, indicating the theoretical possibility of tumor induction in mice by 2,5-toluenediamine sulfate that could not be established under the conditions of this test.

V. DISCUSSION

There was no significant association between compound administration and accelerated mortality in either sex of either species. Adequate numbers of animals in all groups survived sufficiently long to be at risk from late-developing tumors.

Although the incidence of interstitial-cell neoplasms of the testis was statistically significant in each dosed male rat group, development of these tumors was not considered attributable to compound administration since spontaneous incidence of these neoplasms in male Fischer 344 rats is both high and variable. It should also be noted that control rats were housed in a separate room from dosed rats. There were no other neoplasms occurring in male rats at statistically significant incidences, and none of the incidences of neoplasms observed in female rats were statistically significant.

The only site of significantly increased tumor incidence among dosed female mice was the lungs. The combined incidence of alveolar/ bronchiolar adenomas and alveolar/bronchiolar carcinomas was statistically significant for the high dose group. The combined incidences of these tumors in both high and low dose female mouse groups were elevated relative to historical controls. However, it should be noted that high dose control mice were housed in a separate room from dosed mice and received in separate shipments from dosed mice. Because of these factors, this increased incidence does not provide

sufficient evidence of a compound-related effect. No significant increase in tumor incidence was observed among dosed male mice.

Under the conditions of this bioassay, sufficient evidence was not provided to conclusively demonstrate the carcinogenicity of 2,5-toluenediamine sulfate in either Fischer 344 rats or B6C3F1 mice.

VI. BIBLIOGRAPHY

- Ames, B.N., H.O. Kammen, and E. Yamasaki, "Hair Dyes are Mutagenic: Identification of a Variety of Mutagenic Ingredients." <u>Pro-</u> <u>ceedings of the National Academy of Science U.S.A.</u> 72:2423-2427, 1975.
- Anthony, H.M., and G.M. Thomas, "Tumors of the Urinary Bladder: An Analysis of the Occupations of 1,030 Patients in Leeds, England." Journal of the National Cancer Institute 45:879-895, 1970.
- Armitage, P., <u>Statistical Methods in Medical Research</u>, Chapter 14. J. Wiley & Sons, New York, 1971.
- Berenblum, I., editor, <u>Carcinogenicity Testing</u>. International Union Against Cancer, Technical Report Series, Vol. 2. International Union Against Cancer, Geneva, 1969.
- Chemical Abstracts Service, The Chemical Abstracts Service (CAS) Ninth Collective Index, Volumes 76-85, 1972-1976. American Chemical Society, Washington, D.C., 1977.
- Cockrell, B.Y. and F.M. Garner, "Interstitial-Cell Tumors of the Testis in Rats." Comparative Pathology Bulletin 8:2-4, 1976.
- Cox, D.R., <u>Analysis of Binary Data</u>, Chapters 4 and 5. Methuen and Co., Ltd., London, 1970.
- Cox, D.R., "Regression Models and Life-Tables." Journal of the Royal Statistical Society, Series "B" 34:187-220, 1972.
- Gart, J.J., "The Comparison of Proportions: A Review of Significance Tests, Confidence Limits, and Adjustments for Stratification." International Statistical Institute Review 39:148-169, 1971.
- Hawley, G.G., editor, <u>The Condensed Chemical Dictionary</u>, 8th edition. Van Nostrand Reinhold Company, New York, 1971.
- Hoover, R. and J. Fraumeni, Jr., "Cancer Mortality in U.S. Counties with Chemical Industries." <u>Environmental Research</u> 9:196-207, 1975.
- Kaplan, E.L., and P. Meier, "Nonparametric Estimation from Incomplete Observations." Journal of the American Statistical Association 53:457-481, 1958.

- Kiese, M., and E. Rauscher, "The Absorption of p-toluenediamine Through Human Skin in Hair Dyeing." <u>Toxicology and Applied</u> <u>Pharmacology</u> 13:325-331, 1968.
- Kiese, M., M. Rachor, and E. Rauscher, "The Absorption of Some Phenylenediamines Through the Skin of Dogs." <u>Toxicology and Applied</u> <u>Pharmacology</u> 12:495-507, 1968.
- Linhart, M.S., J.A. Cooper, R.L. Martin, N.P. Page, and J. A. Peters, "Carcinogenesis Bioassay Data System." <u>Computers and Biomedical</u> Research 7:230-248, 1974.
- Miller, R.G., <u>Simultaneous Statistical Inference</u>. McGraw-Hill Book Co., New York, 1966.
- Saffiotti, U., R. Montesano, A.R. Sellakumar, F. Cefis, and D.G. Kaufman, "Respiratory Tract Carcinogenesis in Hamsters Induced by Different Numbers of Administration of Benzo (a) Pyrene and Ferric Oxide." Cancer Research 32:1073-1079, 1972.
- Sax, N.I. <u>Dangerous Properties of Industrial Materials</u>. Van Nostrand Reinhold Company, New York, 1975.
- Society of Dyers and Colourists, <u>Colour Index</u>, 3rd edition, Volume 3. Yorkshire, England, p. 3260, 1971.
- Staats, E.B., Comptroller General of the United States. <u>Cancer and</u> <u>Coal Tar Hair Dyes: An Unregulated Hazard to Consumers.</u> Report to the Subcommittee on Oversight and Investigations, Committee on Interstate and Foreign Commerce, House of Representatives, Washington, D.C., December 6, 1977.
- Tarone, R. E., "Tests for Trend in Life-Table Analysis." <u>Biometrika</u> 62:679-682, 1975.
- U.S. International Trade Commission, <u>Imports of Benzenoid Chemicals</u> and Products, 1974. USITC Publication 762, U.S. Government Printing Office, Washington, D.C., 1976.
- Wynder, E.L., J. Onderdonk, and N. Mantel, "An Epidemiological Investigation of Cancer of the Bladder." <u>Cancer 161</u>:1388-1407, 1963.

APPENDIX A

SUMMARY OF THE INCIDENCE OF NEOPLASMS IN RATS TREATED WITH 2,5-TOLUENEDIAMINE SULFATE

TABLE AI SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE RATS TREATED WITH 2,5-TOLUENEDIAMINE SULFATE

	HIGH DOSE CONTROL (UNTR) 01-0084	LOW DOSE CONTROL (UNTR) 01-0037	LOW COSE 01-0039	HIGH DOSE 01-0090
ANIMALS INITIALLY IN STUDY	25	50	50	50
ANIMALS NECROPSIED	25	46	49	49
ANIMALS EXAMINED HISTOPATHOLOGICALLY**	25	46	48	49
INTEGUMENTARY SYSTEM				
*SKIN	(25)	(46)	(49)	(49)
SQUAMOUS CELL CARCINOMA	- /		1 (2%)	
*SUBCUT TISSUE	(25)	(46)	(49)	(49)
FIBROMA LIPOMA			1 (2%) 1 (2%)	1 (2%)
HE MANGIOSARCOMA			1 (23)	1 (2%)
NEUROFIBROMA				1 (2%)
*TRACHEA ADENOCARCINOMA, NOS, METASTATIC	(11)	(45) 1 (2%)	(46)	(47)
#LUNG UNCIFFERENTIATED CARCINOMA METAS	(25)	(46)	(48)	(49) 1 (2%)
ADENOCARCINOMA, NOS, METASTATIC ALVECLAR/BRONCHIOLAR ADENOMA	2 (8%)	1 (2%)	1 (3) #1	
ALVEOLAR/BRONCHIOLAR CARCINOMA	2 (0%) 1 (4%)		1 (2%)	
PAPIILARY ADENOCARCINOMA, METAST PHEOCHROMOCYTOMA, METASTATIC	1 (4%)		1 (2%)	
HEMATOFOIETIC SYSTEM				
* MULTIPLE ORGANS	(25)	(46)	(49)	(49)
MALIGNANT LYMPHOMA, NOS MALIG.LYMPHOMA, HISTIOCYTIC TYPE			1 (2%) 1 (2%)	
UNDIFFERENTIATED LEUKENIA	2 (8%)	1 (2%)	1 (2.4)	
MYELCMONOCYTIC LEUKEMIA		· • - •	2 (4%)	5 (10%
LYMPHOCYTIC LEUKEMIA	2 (8%)		1 (2%)	1 (2%)

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY
 NUMBER OF ANIMALS NECROPSIED
 ** EXCLUDES PARTIALLY AUTOLYZED ANIMALS

TABLE A1 (CONTINUED)

	HIGH DOSE CONTROL (UNTR) 01-0084	LOW DOSE CONTROL (UNTR) 01-0037	LOW DOSE 01-0039	HIGH DOSE 01-0090
#LYMPH NODE ADENOCASCINOMA, NOS, METASTATIC	(24)	(38) 1 (3%)	(39)	(43)
#MEDIASTINAL L.NODE UNDIFFERENTIATED CARCINOMA METAS	(24)	(38)	(39)	(43) 1 (2%)
ABDOMINAL LYMPH NODE UNEIFFFRENTIATED CARCINOMA METAS	(24)	(38)	(39)	(43) 1 (2%)
LIVER MYELOMONOCYTIC LEUKEMIA GRANULOCYTIC LEUKEMIA	(25)	(46)	(48)	(49) 1 (2%) 1 (2%)
#THYMUS THYMOMA	(22)	(38)	(39) 1 (3%)	(28)
IRCULATORY SYSTEM NONF IGFSTIVE SYSTEM				
*LIVER *LIVER UNDIFFERENTIATED CARCINOMA METAS NFOPLASTIC NODULE HEPATOCELLULAR CARCINOMA	(25)	(46)	(48) 1 (2%) 1 (2%)	(49) 1 (2%)
PANCREAS UNDIFFERENTIATED CARCINOMA ADENOMA, NOS	(25)	(42)	(48)	(48) 1 (2%) 1 (2%)
*STONACH SQUAMOUS CELL PAPILLONA BASAI-CELL CARCINOMA	(24) 1 (4%) 1 (4%)	(45)	(47)	(49)
#JEJUNUM CYSTADENOCARCINOMA, NOS	(24)	(43)	(48)	(48) 1 (2%)
COLON ADENOCARCINOMA, NOS	(24)	(43)	(47)	(48) 1 (2%)
PINARY SYSTEM				
#KIDNEY TUBULAR-CELL_ADENOMA	(24)	(46)	(48)	(49) <u>1 (2%)</u>

* NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIZD

TABLE A1 (CONTINUED)

	HIGH DOSE CONTROL (UNTR) 01-0084	LOW DOSE CONTROL (UNTR) 01-0037	LOW DOSE 01-0039	HIGH DOSE 01-0090
#URINARY BLADDER PAPILLOMA, NOS TRANSITIONAL-CELL CARCINOMA	(23)	(42)	(48) 1 (2%) 1 (2%)	(45) 1 (2%)
NDOCRINE SYSTEM				
<pre>#PITUITARY ADENOMA, NOS CHROMOPHOBE ADENOMA BASOPHIL ADENOMA</pre>	(21) 1 (5%) 2 (10%)	(41) 2 (5%) 10 (24%)	(45) 3 (7%)	(40) 3 (8%)
*ADRENAL ADENOCARCINOMA, NOS, METASTATIC PHECCHROMOCYTOMA PHECCHROMOCYTOMA, MALIGNANT	(25) 2 (8系) 2 (8系)	(43) 1 (2%) 6 (14%)	(48) 2 (4 %)	(48) 1 (2%)
<pre>#THYROID ADENOMA, NOS ADENOCARCINOMA, NOS PAPILLARY ADENOCARCINOMA C-CELL ADENOMA C-CELL CARCINOMA CYSTADBNOCARCINOMA, NOS PAPILLARY CYSTADENOCARCINOMA,NOS</pre>	(23)	(45) 1 (2%) 2 (4%) 1 (2%)	(46) 3 (7%) 1 (2%)	(47) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%)
*PANCREATIC ISLETS ISLET-CELL ADENOMA	(25) 2 (8%)	(42) 2 (5%)	(48) 4 (8%)	(48) 1 (2%)
SPRODUCTIVE SYSTEM				
MAMMARY GLAND FIBROADENOMA	(25) 1 (4%)	(46)	(49) 1 (2%)	(49)
*PREPUTIAL GLAND CARCINOMA,NOS ADENCMA, NOS	(25) 1 (4%) 1 (4%)	(46)	(49)	(49) 2 (4%)
PROSTATE PARAGANGLIOMA, NOS	(23)	(45) 1 (2%)	(47)	(46)
TESTIS	(24) 19 (79 %)	(45) 33_(73%)	(48) .43.(90 %)	(48) 47_(98%)

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

TABLE A1 (CONTINUED)

	HIGH DOSE CONTROL (UNTR) 01-0084	LOW DOSE CONTROL (UNTR) 01-0037	LOW DOSE 01-0039	HIGH DOSE 01-0090
* SCRCTUM LEIONYOMA	(25)	(46)	(49)	(49) 1 (2%)
IERVOUS SYSTEM				
#BRAIN ASTROCYTOMA	(25)	(44) 1 (2%)	(48)	(48)
SPECIAL SENSE ORGANS				
*FAR FIBRCMA	(25)	(46)	(49)	(49) 1 (2%)
*EAR CANAL SQUAMOUS CELL CARCINOMA	(25) 1 (4%)	(46)	(49)	(49)
USCULOSKELETAL SYSTEM				
NONE				
BODY CAVITIES				
*BODY CAVITIES MFSOTHELIOMA, NOS	(25)	(46)	(49) 1 (2%)	(49)
*MEDIASTINUM Alveolar/bronchiolar ca, metasta	(25) 1 (4%)	(46)	(49)	(4 9)
*PLEURA	(25) 1 (4%)	(46)	(49)	(49)

* NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

TABLE A1 (CONCLUDED)

	HIGH DOSE CONTROL (UNTR) 01-0084	LOW DOSE CONTROL (UNTR) 01-0037	LOW DOSE 01-0039	HIGH DOSE 01-0090
NIMAL DISPOSITION SUMMARY				
ANIMALS INITIALLY IN STUDY	25	50	50	50
NATURAL DEATHØ	3	6	5	3
MORIFUND SACRIFICE	4	2	5	11
SCHEDULED SACRIFICE	5	15	5	
ACCIDENTALLY KILLED				
TERMINAL SACRIFICE	13	27	35	36
ANIMAL MISSING				
INCLUDES AUTOLYZED ANIMALS				
UMOR SUMMARY				
TOTAL ANIMALS WITH PRIMARY TUMORS*	22	34	45	48
TOTAL PRIMARY TUMORS	41	61	72	77
TOTAL ANIMALS WITH BENIGN TUMERS	20	33	44	47
TOTAL BENIGN TUMORS	31	55	58	59
TOTAL ANIMALS WITH MALIGNANT TUMORS	9	5	9	17
TOTAL MALIGNANT TUMORS	10	5	12	18
TOTAL HALIGNANT TUNORS	10	2	12	10
TOTAL ANIMALS WITH SECONDARY TUMORS	# 2	1	1	1
TOTAL SECONDARY TUMORS	3	4	1	4
TOTAL ANIMALS WITH TUMORS UNCERTAIN	_			
BENIGN OF MALIGNANT		1	2	
TOTAL UNCERTAIN TUMORS		, 1	2	
LOINE CROCKINER TORORD		,	-	
TOTAL ANIMALS WITH TUMORS UNCERTAIN	-			
PRIMARY OR METASTATIC				
TOTAL UNCERTAIN TUMORS				
PRIMARY TUMORS: ALL TUMORS EXCEPT S	ECONDARY THMORS			
SECONDARY TUMORS: METASTATIC TUMORS				

A-7

TABLE A2
SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE RATS
TREATED WITH 2,5-TOLUENEDIAMINE SULFATE
TREATED WITH 2,5 TODOENDDI LAND OOD THE

. .

	HIGH DOSE CONTROL (UNTR) 02-0084	LOW DOSE CONTROL (UNTR) 02-0037	LOW DOSE 02-0039	HIGH DOSE 02-0090
ANIMALS INITIALLY IN STUDY ANIMALS N5CROPSIED ANIMALS EXAMINED HISTOPATHOLOGICALLY**	25 23 23	50 49 49	50 50 50	50 50 50
INTEGUMENTARY SYSTEM				
*SKIN	(23)	(49)	(50) 1 (2%)	(50)
SQUAMOUS CELL CARCINOMA SEBACEOUS ADENOCARCINOMA FIBROSARCOMA	1 (4%)		(2%)	1 (2%)
*SUBCUT TISSUE SQUAMOUS CELL CARCINOMA	(23)	(49)	(50)	(50) 1 (2%)
ESPIRATORY SYSTEM				
#LUNG ADENOCARCINOMA, NOS, METASTATIC HEPATOCFILULAR CARCINOMA, METAST	(23)	(49) 1 (2系) 1 (2系)	(50) 1 (2%)	(50)
-	1 (4%)	1 (2%)		1 (2%)
EMATOPOIPTIC SYSTEM				
*MULTIPLE OFGANS MALIG.LYMPHOMA, LYMPHOCYTIC TYPE LEUKEMIA,NOS UNDIFFERENTIATED LEUKEMIA MYELOMONOCYTIC LEUKEMIA MONOCYTIC LEUKEMIA	(23)	(49) (50) 2 (4%)	(50)	(50)
	2 (04)			1 (2%)
	2 (9%)	2 (4%)	2 (4%)	8 (16%)
#PENAL LYMPH NODE ADENOCARCINOMA, NOS, METASTATIC	(21)	(41) 1 (2%)	(47)	(49)
*THYMUS MALIGNANT LYMPHOMA, NOS	(20)	(42)	(43)	(44) 1 (2%)

NONE

}

* NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED **EXCLUDES PARTIALLY AUTOLYZED ANIMALS

TABLE A2 (CONTINUED)

	HIGH DOSE CONTROL (UNTR) 02-0084	LOW DOSE CONTROL (UNTR) 02-0037		HIGH DOSE 02-0090
DIGESTIVE SYSTEM				
#LIVER ADENOCARCINONA, NOS, METASTATIC NEOFLASTIC NODULE HEPATOCELLULAR CARCINONA	(23) 2 (9%)	(49) 1 (2%) 2 (4%)	(50)	(49) 1 (⊃ ₹)
*STONACH SQUAMOUS CELL PAPILLOMA	(23)	2 (4%) (48)	1 (2%) (50)	1 (2%) (49) 1 (2%)
<pre>#ILEUN LEIOHYOSARCONA</pre>	(23)	(47)	(50)	(49) 1 (2%)
URINARY SYSTEM				
#URINARY BLADDER PAPIILOMA, NOS	(22)	(41)	(47)	(50) 1 (2%)
ENDOCRINE SYSTEM				
<pre>#PITUITARY ADEMOMA, NOS ADENOCARCINOMA, NOS CHROMOPHOBE ADENOMA</pre>	(21) 1 (5%) 7 (33%)	(43) 3 (7%) 2 (5%) 15 (35%)	(48) 17 (35%)	(43) 10 (23%)
#ADRENAL PHEOCHROMOCYTOMA PHEOCHROMOCYTOMA, MALIGNANT	(23) 2 (9%) 1 (4%)	(46) 2 (4%)	(50) 1 (2%)	(48) 1 (2%)
*THYROID ADENOMA, NOS ADENOCARCINOMA, NOS C-CELL ADENOMA	(21) 2 (10%)	(47) 1 (2%) 2 (4%) 1 (2%)	(48)	(49) 1 (2%)
C-CELL CARCINOMA	1 (5%)	1 (2 %)	3 (6%)	
*THYROIC FOLLICLE PAPILLARY CYSTADENOCARCINOMA, NOS	(21) 1 (5%)	(47)	(48)	(4 9)
REPRODUCTIVE SYSTEM				
*MAMMARY GLAND ADENONANQS	(23)	(49)	(50)	(50)

* NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

TABLE A2 (CONTINUED)

	HIGH DOSE CONTROL (UNTR) 02-0084	LOW DOSE CONTROL (UNTR) 02-0037	02-0039	HIGH DOSE 02-0090
ADENCCARCINOMA, NOS PAPILLARY ADENOCARCINOMA PAPILLARY CYSTADENOMA, NOS PAPILLARY CYSTADENOCARCINOMA,NOS INFILTRATING DUCT CARCINOMA	2 (9%) 1 (4%)	1 (2%) 1 (2%)	1 (2%)	1 (2%) 1 (2%)
FIBROADENOMA	4 (17%)	4 (8%)	6 (12%)	9 (18%
*CLITORAL GLAND CARCINOMA,NOS	(23)	(49)	(50)	(50) 1 (2%)
#UTERUS ADENOCARCINOMA, NOS ENDOMETRIAL STROMAL POLYP HEMANGIOMA	(23) 6 (26%)	(48) 4 (8%) 10 (21%)	(49) 1 (2%) 7 (14%) 1 (2%)	(45) 1 (2%) 7 (16%
#UTERUS/ENDOMETRIUM ADENCCARCINOMA, NOS	(23)	(48)	(49) 2 (4%)	(45)
#OVARY TUBULAR ADENOMA	(22)	(47)	(50)	(46) 1 (2%)
ERVOUS SYSTEM				
NONE				
PECIAL SENSE ORGANS				
*EAR Squamous cell carcinoma	(23)	(49)	(50) 2 (4%)	(50)
*EAR CANAL Fibroma	(23)	(49) 1 (2%)	(50)	(50)
USCULOSKELETAL SYSTEM				
NONE				
BODY CAVITIES				
*BODY CAVITIES MESCTHELIOMA, MALIGNANT	(23)	(49) <u>1 (2%)</u>	(50)	(50)

* NUMBER OF ANIMALS WITH TISSUE * NUMBER OF ANIMALS NECROPSIED

	CONTROL (UNTR)	LOW DOSE CONTROL (UNTR) 02-0037	LOW DOSE 02-0039	HIGH DOSI 02-0090
*ABDCHINAL CAVITY Sarcona, nos Leionyosarcona	(23)	(49)	(50) 1 (2%) 1 (2%)	(50) 1 (2%)
*PBRITONEUM	(23)	(49)	(50)	(50)
ADENOCARCINOMA, NOS, METASTATIC LIPOMA			1 (2%)	1 (2%)
ALL OTHER SYSTEMS	Į			
DIA PHRAGM RHABDONYOSA RCOMA				1
ANIMAL DISPOSITION SUMMARY				
ANIMALS INITIALLY IN STUDY	25	50	50	50
NATURAL DEATHD	3	5	2.	
MORIBUND SACRIFICE	3 5 5	7	11	11
SCHEDULED SACRIFICE Accidentally killed	5	15	5	
TERMINAL SACRIFICE	12	23	32	39
ANIMAL MISSING	, 2	<i>2</i> , 3	32	53

TABLE A2 (CONCLUDED)

Ċ	IGH DOSE ON TROL (UNTR) 02-0084	LOW DOSE CONTROL (UNTR) 02-0037	LOW DOSE 02-0039	HIGH DOSE 02-0090
TUMOR SUMMARY				
TOTAL ANIMALS WITH PRIMARY TUMORS* Total primary tumors	19 34	32 56	34 47	33 53
TOTAL ANIMALS WITH BENIGN TUMCRS TOTAL BENIGN TUMORS	18 23	27 39	28 32	23 33
TOTAL ANIMALS WITH MALIGNANT TUMORS TOTAL MALIGNANT TUMORS	8 9	15 17	14 15	17 20
TOTAL ANIMALS WITH SECONDARY TUMORS# TOTAL SECONDARY TUMORS		2 4	1 2	
TOTAL ANIMALS WITH TUMORS UNCERTAIN- BENIGN OR MALIGNANT TOTAL UNCERTAIN TUMORS	2 2			
TOTAL ANIMALS WITH TUMORS UNCERTAIN- PRIMARY OR METASTATIC TOTAL UNCERTAIN TUMORS				

APPENDIX B

SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MICE TREATED WITH 2,5-TOLUENEDIAMINE SULFATE

TABLE B1
SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE MICE
TREATED WITH 2,5-TOLUENEDIAMINE SULFATE

	HIGH DOSE CONTROL (UNTR) 05-0077	LOW DOSE CONTROL (UNTR) 05-0037	LOW DOSE 05-0039	HIGH DOSE 05-0089
ANIMALS INITIALLY IN STUDY ANIMALS NECROPSIED ANIMALS EXAMINED HISTOPATHOLOGICALLY**	50 46	50 48 48	50 49 48	50 49 49
INTEGUMENTARY SYSTEM				
*SUBCUT TISSUE OSTECMA	• •	(48)	(49) 1 (2%)	(49)
RESPIRATORY SYSTEM				
<pre>#LUNG HEPATOCELLULAR CARCINOMA, METAST ALVEOLAR/BRONCHIOLAR ADENOMA ALVEOLAR/BRONCHIOLAR CARCINOMA</pre>	(45) 1 (2%) 7 (16%) 4 (9%)	(48) 6 (13%)	(47) 5 (11%) 1 (2%)	(49) 2 (4%) 5 (10%) 5 (10%)
IEMATOPOIFTIC SYSTEM				
*MULTIPLE ORGANS MALIGNANT LYMPHOMA, NOS MALIG.LYMPHOMA, HISTIOCYTIC TYPE	(46)	(48) 2 (4%) 2 (4%)	(49) 4 (8%)	(49) 2 (4%)
*SPLEEN HEMANGIOMA MALIG.LYMPHOMA, HISTIOCYTIC TYPE	(45) 1 (2%)	(47) 1 (2%)	(48) 1 (2%)	(43)
#MANDIBULAR L. NODE MALIG.LYMPHOMA, HISTIOCYTIC TYPE	(35) 1 (3%)	(44)	(44)	(36)
*MESENTERIC L. NODE Malignant Lymphoma, Nos	(35)	(44)	(44)	(36) 1 (3%)
<pre>#LIVER MALIG.LYMPHOMA, HISTIOCYTIC TYPE</pre>	(45)	(48)	• •	(49) 1 (2%)

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY
 NUMBER OF ANIMALS NECROPSIED
 ** EXCLUDES PARTIALLY AUTOLYZED ANIMALS

	HIGH DOSE CONTROL (UNTR) 05-0077	LOW DOSE CONTROL (UNTR) 05-0037	LOW DOSE 05-0039	HIGH DOSE 05-0089
DIGESTIVE SYSTEM				
*LIVER	(45)	(48)	(48)	(49)
NEOPLASTIC NODULE HEPATOCELLULAR CARCINOMA HENANGIOMA	10 (22%)	7 (15%) 1 (2%)	8 (17%)	2 (4%) 16 (33%)
*STOMACH SQUAMOUS CELL PAPILLOMA SQUAMOUS CELL CARCINOMA	(42) 1 (2%)	(47) 1 (2%)	(46)	(48)
JRINARY SYSTEM				
NONE				
ENDOCRINE SYSTEM				
* ADRENAL Pheochromocytoma	(43)	(45)	(45)	(44) 1 (2%)
*THYROID Follicular-cell Adenoma	(40)	(47) 1 (2 %)	(46)	(46)
REPRODUCTIVE SYSTEM				
NONE				
NERVOUS SYSTEM				
NONE				
SPECIAL SENSE ORGANS				
*HARDERIAN GLAND Adenoma, nos Papillary Cystadenoma, nos	(46)	(48)	(49) 1 (2%)	(49) 1 (2%)
*EAR CANAL Squamous cell carcinoma	(46) 1 (2%)	(48)	(49)	(49)
NUSCULOSKFLETAL SYSTEM				
NONE				

TABLE B1 (CONCLUDED)

		LOW DOSE CONTROL (UNTR) 05-0037		HIGH DOSE 05-0089
DY CAVITIES				
NON E				
L OTHER SYSTEMS				
NONE				
IMAL DISPOSITION SUMMARY				
ANIMALS INITIALLY IN STUDY	50	50	50	50
NATURAL DEATHØ	7	3	3	7
MORIBUND SACRIFICE SCHEDULED SACRIFICE	1 5	5		1 5
ACCIDENTALLY KILLED	5	5		2
TERMINAL SACRIFICE Animal missing	37	42	47	37
INCLUDES AUTOLYZED ANIMALS				
MOR SUMMARY				
TOTAL ANIMALS WITH PRIMARY TUMORS*	21	17	19	27
TOTAL PRIMARY TUMORS	25	21	21	34
TOTAL ANIMALS WITH BENIGN TUMCRS	8	2	7	7
TOTAL BENIGN TUMORS	8	3	7	7
TOTAL SNEWLES HERE MALLONSHE THNOLD	⁴ 15	15	13	23
TOTAL ANIMALS WITH MALIGNANT TUMORS TOTAL MALIGNANT TUMORS	17	18	14	25
TOTAL ANIMALS WITH SECONDARY TUMORS				2 2
TOTAL SECONDARY TUMORS	1			2
TOTAL ANIMALS WITH TUMORS UNCERTAIN	-			
BENIGN OR MALIGNANT				2
TOTAL UNCERTAIN TUMORS				2
TOTAL ANIMALS WITH TUMORS UNCERTAIN	-			
PRIMARY OR METASTATIC				
TOTAL UNCERTAIN TUMORS				
PRIMARY TUMORS: ALL TUMORS EXCEPT S	ECONDARY TUMORS			

	HIGH DOSE CONTROL (UNTR)	LOW DOSE CONTROL (UNTR)		HIGH DOSE
	06-0077	06-0037	06-0039	06-0089
ANIMALS INITIALLY IN STUDY ANIMALS MISSING	50	50	50 1	50
ANIMALS NECROPSIED	46	48	45	47
ANIMALS EXAMINED HISTOPATHOLOGICALLY**	* 46	47	43	46
INTEGUMENTARY SYSTEM				
*SKIN	(46)	(48)	(45)	(47)
FIBRCSARCOMA	2 (4%)	x - <i>y</i>		· · ·
*SUBCUT TISSUE	(46)	(48)	(45) 1 (2%)	(47)
SARCOMA, NOS LEIOMYOSARCOMA		1 (2%)		
		1 (2/)		
RESPIRATORY SYSTEM				
#LUNG		(46)	(42)	(46)
HEPATOCELLULAR CARCINOMA, METAST Alveolar/bronchiolar adenoma	1 (2%)	3 (7%)	1 (2%) 6 (14%)	7 (15%)
ALVEOLAR/BRONCHIOLAR CARCINOMA		1 (2%)		1 (2%)
HEMATOPOIETIC SYSTEM				
*MULTIPLE ORGANS	(46)	(48)	(45)	(47)
MALIGNANT LYMPHOMA, NOS	3 (7%)	1 (2%)	1 (2%)	3 (6%)
MALIG.LYMPHONA, UNDIFFER-TYFE Malig.lymphona, histiocytic type	6 (13%)	2 (4%)	3 (7%)	1 (2%)
LYMPHOCYTIC LEUKEMIA	1 (2%)	- • • •		
#SPLEEN	(43)	(46)	(42)	(42)
HEMANGIOSARCOMA		1 (2%)	1 (2%)	2 (5.7)
MALIG.LYMPHOMA, HISTIOCYTIC TYPE		1 (2%)		2 (5%)
#LYMPH NODE MALIGNANT LYMPHOMA, NOS	(41)	(39)	(37)	(32) 1 (3%)
#PEYERS PATCH	(43)	(44)	(42)	(42)
MALIG, LYMPHOMA, HISTLOCYTIC TYPE	1_(28)			

TABLE B2 SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE MICE TREATED WITH 2,5-TOLUENEDIAMINE SULFATE

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY
 NUMBER OF ANIMALS NECROPSIED
 ** EXCLUDES PARTIALLY AUTOLYZED ANIMALS

	HIGH DOSE CONTROL (UNTR) 06-0077	LOW DOSE CONTROL (UNTR) 06-0037	LOW DOSE 06-0039	HIGH DOSE 06-0089
#DUODENUM MALIGNANT LYMPHOMA, NOS	(43)	(44)	(42)	(42) 1 (2%)
*THYMUS MALIGNANT LYMPHOMA, NOS	(27)	(31) 1 (3%)	(29)	(29)
IRCULATCRY SYSTEM				
*PULMONARY ARTERY ADENOCARCINOMA, NOS, METASTATIC	(46)	(48)	(45) 1 (2%)	(47)
IGESTIVE SYSTEM				
<pre>#LIVER HEPATOCELLULAR CARCINOMA FIBROSARCOMA</pre>	(45) 4 (9%)	(47) 1 (2%) 1 (2%)	(42) 2 (5%)	(46) 4 (9%)
*BILE DUCT BILE DUCT CARCINOMA	(46)	(48)	(45)	(47) 1 (2%)
#STOMACH SQUAMOUS CELL PAPILLOMA	(42) 3 (7%)	(44) 1 (2%)	(42)	(43)
#JEJUNUM ADENOCARCINOMA, NOS	(43)	(44)	(42) 1 (2%)	(4 2)
COLON LBIOMYOSARCONA	(41)	(40) 1 (3%)	(41)	(43)
RINARY SYSTEM				
NON E				
NDOCRINE SYSTEM				
<pre>#PITUITARY CARCINOMA,NOS ADENOMA, NOS</pre>	(37) 6 (16%)	(42) 1 (2%) 2 (5%)	(38) 1 (3%)	(38)
#ADRENAL CORTICAL ADENONA	(43)	(45)	(38)	(41)

	HIGH DOSE CONTROL (UNTR) 06-0077	LOW DOSE CONTROL (UNTR) 06-0037	LOW DOSE 06-0039	HIGH DOSE 06-0089
PHECCHROMOCYTOMA		1 (2%)		
<pre>#THYROID PAPILLARY ADENOCARCINOMA</pre>	(30)	(43)	(36) 1 (3%)	(34)
#PANCREATIC ISLETS ISLET-CELL ADENOMA	(41) 1 (2%)	(44)	(42)	(42)
REPRODUCTIVE SYSTEM				
*MAMMARY GLAND Adenocarcinoma, nos	(46) 1 (2%)	(48)	(45)	(47)
#UTERUS LEIOMYOSARCOMA ENDOMETRIAL STROMAL POLYP	(43)	(45) 1 (2%) 3 (7%)	(41)	(42)
#OVARY PAPILLARY CYSTADENOMA, NOS LUTECMA	(41) 1 (2%)	(45)	(36)	(39) 1 (3%)
TUBULAR ADENOMA		1 (2%)		1 (3%)
IERVOUS SYSTEM				
NON E				
PECIAL SENSE ORGANS				
*HARD3RIAN GLAND PAPIILARY CYSTADENOMA, NOS	(46)	(48)		(47) 1 (2%)
NUSCULOSKELETAL SYSTEM				
NONE		************		
ODY CAVITIES				
NONE				
LL OTHER SYSTEMS				
_NONE				
NUMBER OF ANIMALS WITH TISSUE EX. NUMBER OF ANIMALS NECROPSIED	AMINED MICROSCOPIC	ALLY		

TABLE B2 (CONCLUDED)

	HIGH DOSE CONTROL (UNTR) 06-0077	LOW DOSE CONTROL (UNTR) 06-0037	LOW COSE 06-0039	HIGH DOSE 06-0089
NIMAL DISPOSITION SUMMARY				
ANIMALS INITIALLY IN STUDY	50	50	50	50
NATURAL DEATHƏ	8	6	9	10
MORIBUND SACRIFICE	2	2	1	2
SCHECULED SACRIPICE Accidentally killed	5	5		5
TERMINAL SACRIFICE	35	37	39	33
ANIMAL MISSING		57	1	55
INCLUDES AUTOLYZED ANIMALS				
UMOR SUMMARY				
TOTAL ANIMALS WITH PRIMARY TUNORS*		20	15	22
TOTAL PRIMARY TUMORS	32	24	17	24
TOTAL ANIMALS WITH BENIGN TUNCRS	12	11	7	10
TOTAL BENIGN TUMORS	13	11	7	10
TOTAL ANIMALS WITH MALIGNANT TUMORS	18	11	9	12
TOTAL MALIGNANT TUMORS	19	13	10	14
TOTAL ANIMALS WITH SECONDARY TUMORS	#		2	
TOTAL SECONDARY TUMORS			2	
TOTAL ANIMALS WITH TUMORS UNCERTAIN	_			
BENIGN OR MALIGNANT				
TOTAL UNCERTAIN TUMORS				
TOTAL ANIMALS WITH TUMORS UNCERTAIN	-			
PRIMARY OR METASTATIC				
TOTAL UNCERTAIN TUMORS				
PRIMARY TUMORS: ALL TUMORS EXCEPT S				
SECONDARY TUMORS: METASTATIC TUMORS	OR TUMORS INVA	SIVE INTO AN ADJ	ACENT ORGAN	

APPENDIX C

SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN RATS TREATED WITH 2,5-TOLUENEDIAMINE SULFATE

TABLE CI		
SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE RATS TREATED WITH 2.5-TOLUENEDIAMINE SULFATE		
······································		

. . .

.

▝▝▙▙▁▋▙▙▙▝▙▝▙▝▙▙▙▙▙▙▙▙▙▙▙▙▙▙▙▙▙▙▙▙▙▙₩₩₩₩₩₩₩₩₩				
	HICH DOSE CONTROL (UNTR) 01-0084	LOW DOSE CONTROL (UNTR) 01-0037	LCW DOSE 01-0039	HIGH DOSE 01-0090
ANIMALS INITIALLY IN STUDY	25	50	50	50
ANIMALS NECROPSIED	25	46	49	49
ANIMALS EXAMINED HISTOPATHOLOGICALLY	** 25	46 	48	49
INTEGUMENTARY SYSTEM				
*SKIN	(25)	(46)	(49)	(49)
EPIDERMAL INCLUSION CYST				1 (2%)
ABSCESS, NOS			1 (2%)	
NECROSIS, NOS	1 (4%)			
*SUBCUT TISSUF	(25)	(46)	(49)	(49)
GRANULATION, TISSUE			1 (2%)	
SCAR				2 (4%)
NECROSIS, NOS			1 (2%)	
RESPIRATORY SYSTEM *LARYNX	(25)	(46)	(49)	(49)
INFLAMMATION ACUTE AND CHRONIC INFLAMMATION, CHRONIC	1 (4%) 7 (28%)			
#TRACHEA	(11)	(45)	(46)	(47)
INFLAMMATION, NOS	1 (9%)	9 (20%)	1 (2%)	
INFLAMMATION, CHRONIC		10 (22%)		
#LUNG/BRONCHUS	(25)	(46)	(48)	(49)
BRONCHIECTASIS	2 (8%)			
INFLAMMATION, FOCAL	1 (4%)			
ABSCESS, NOS		0 (177)	1 (2%)	
INPLAMMATION, CHRONIC		8 (17%)		
#BRONCHIAL MUCOUS GLA	(25)	(46)	(48)	(49)
ABSCESS, NOS		1 (2%)		
NECROSIS, NOS		1 (2%)		
HYPERPLASIA, ADENCMATOUS		1 (2%)		
#LUNG/BRONCHIOLE	(25)	(46)	(48)	(49)
INFLAMMATION, NOS		1 (2%)		

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY
 NUMBER OF ANIMALS NECROPSIED
 ** EXCLUDES PARTIALLY AUTOLYZED ANIMALS

	HIGH DOSE CONTROL (UNTR) 01-0084	LOW DOSE CONTROL (UNTR) 01-0037	LOW DOSE 01-0039	HIGH DOSI 01-0090
INFLAMMATICN, FOCAL		1 (2%)		
*LUNG EMBRYONAL DUCT CYST	(25)	(46)	(48) 1 (2%)	(49)
ATELECTASIS		1 (2%)		
CONGESTION, NOS		1 (2%)		
EDENA, NOS		1 (2%)		
INFLAMMATION, NOS		1 (2%)		
INFLAMMATION, FOCAL		3 (7%)		
INFLAMMATION, INTERSTITIAL	2 (8%)	1 (2%)		
INFLAMMATION, SUPPURATIVE	4 44 7 1	1 (2%)		
BRONCHOPNEUMONIA, ACUTE	1 (4元) 1 (4元)			
ABSCESS, NOS PNEUMONIA, CHRONIC MURINE		1 (2%)		
INFLAMMATION, CHRONIC	(44%)	1 (2%)		
GRANULCMA, NOS	1 (4%)	(2.4)		
PERIVASCULITIS	(44)	5 (11%)		
*SPLEEN THROMBOSIS, NOS FIBROSIS	(25)	(46) 1 (2%) 1 (2%)	(48)	(47)
INFARCT, HEALED		1 (2%)		
HEMOSIDEROSIS	1 (4%)			
RETICULOCYTOSIS		1 (2%)		
HYPERPLASIA, HEMATOPOIETIC	1 (4%)			
HYPERPLASIA, ERYTHROID	1 (4%)	12 (26%)		
HYPERPLASIA, RETICULUM CELL		8 (17%)	2 (4%)	
HEMATOPOIESIS ERYTHROPOIESIS			1 (2%)	
ENTIMOPOL(515			(2.4)	
#LYMPH NODE	(24)	(38)	(39)	(43)
INFLAMMATION, NOS		ົ້າ (3%)		• •
HYPERPLASIA, NOS		1 (3%)		
PLASMACYTOSIS	1 (4%)	a (0 m)		
HYPERPLASIA, RETICULUM CELL		3 (8%)		
#MEDIASTINAL L.NODE	(24)	(38)	(39)	(43)
PLASMACYTOSIS	(27)	1 (3%)	(22)	(+5)
I DAGUACI IODID				
FRENAL LYMPH NODE	(24)	(38)	(39)	(43)

	HIGH DOSE CONTROL (UNTR) 01-0084	LOW DOSE CONTROL (UNTR) 01-0037	LOW DOSE 01-0039	HIGH DOSE 01-0090
CIRCULATORY SYSTEM				
*LYMPHATIC VESSELS INFLAMMATION, NOS	(25)	(46) 1 (2%)	(49)	(49)
#HEART PERIARTERITIS	(25) 1 (4%)	(46)	(48)	(48)
#HEART/VENTRICLE FIBROSIS	(25)	(46)	(48) 1 (2%)	(48)
<pre>*MYOCARDIUM INFLAMMATION, NOS INFLAMMATION, INTERSTITIAL</pre>	(25)	(46) 1 (2%) 22 (48%)	(48) 1 (2 %)	(48)
INFLAMMATION, CHRONIC FOCAL FIBROSIS FIBROSIS, FOCAL DEGENERATION, NOS	1 (4%) 10 (40%)	3 (7%) 7 (15%)		1 (2%)
*AORTA INFLAMMATION, CHRONIC FOCAL CALCIFICATION, FOCAL	(25) 1 (4%)	(46) 1 (2%)	(49)	(49)
*PULMONARY ARTERY HYPERTROPHY, NOS	(25)	(46) 1 (2%)	(49)	(49)
DIGESTIVE SYSTEM				
*SALIVARY GLAND Cyst, Nos	(24)	(38)	(48) 1 (2%)	(48)
*LIVER CONGESTION, CHRONIC PASSIVE INFLAMMATION, CHRONIC CHOLANGIOFIBROSIS	(25) 1 (4%) 1 (4%)	(46)	(48) 1 (2 %)	(49)
NECROSIS, FOCAL NECROSIS, COAGULATIVE METAMORPHOSIS FATTY HYPERPLASIA, FOCAL	1 (4%) 4 (16%)	3 (7%) 1 (2%) 1 (2%) 23 (50%)	1 (2%)	1 (2%) 1 (2%)
<pre>#LIVER/FERIPORTAL PIBROSIS</pre>	(25)	(46) 1 (2 %)	(48)	(49)
#LIVER/HEPATOCYTES DEGENERATION, NOS	(25)	(46)	(48) <u>1 (2%)</u>	(49)

	01-0084	LOW DOSE CONTROL (UNTR) 01-0037	01-0039	HIGH DOSE 01-0090
HYPERPLASIA, FOCAL			1 (2%)	1 (2%)
*BILE DUCT INFLAMMATION, NOS INFLAMMATION, CHRONIC DIFFUSE	(25)	(46) 6 (13%)	(49) 1 (2%)	(49)
HYPERPLASIA, NOS HYPERPLASIA, FOCAL	6 (24%)	32 (70%) 1 (2%)	6 (12%)	3 (6%)
*PANCREAS INPLAMMATION, NOS HYPERPLASIA, INTRADUCTAL	(25) 1 (4%)	(42) 10 (24%) 1 (2%)	(48)	(48)
<pre>#PANCREATIC DUCT HYPERPLASIA, NOS</pre>	(25) 1 (4%)	(42)	(48)	(48)
*PANCREATIC ACINUS INFLAMMATION, NOS	(25)	(42)	(48) 1 (2%)	(48) 1 (2%)
DEGENERATION, NOS Atrophy, nos		4 (10%)	1 (2%)	1 (2%)
*STOMACH EPIDERMAL INCLUSION CYST ULCEF, NOS HYPERPLASIA, NOS HYPERKERATOSIS ACANTHOSIS	(24) 1 (4%)	(45) 1 (2%) 2 (4%) 6 (13%) 1 (2%) 1 (2%)	(47)	(49)
#GASTRIC MUCOSA ULCER, FOCAL	(24)	(45)	(47)	(49) 1 (2%)
<pre>#PEYERS PATCH HYPERPLASIA, NOS</pre>	(24) 2 (8%)	(43) 7 (16%)	(48)	(48)
#COLON NEMATODIASIS	(24)	(43) 3 (7%)	(47)	(48)
JRINARY SYSTEM				
<pre>#KIDNEY GLOMERULONEPHRITIS, NOS</pre>	(24) 5 (21%)	(46) 33 (72%)	(48)	(49)
INFLAMMATIO», INTERSTITIAL NEPHROPATHY NEPHROSIS, NOS	1 (4%) 16 (67%)	1 (2%)	1 (2%) 42 (88%)	46 (94%
*KIDNEY/CORTEX	(24)	(46)	(48)	(49) 1_(2%)

	HIGH DOSE CONTROL (UNTR) 01-0084	LOW DOSE CONTROL (UNTR) 01-0037	LOW DOSE 01-0039	HIGH DOSE 01-0090
HEMCRRHAGE METAMORPHOSIS FATTY				1 (2%) 1 (2%)
<pre>#KIDNEY/TUBULE NECROSIS, NOS</pre>	(24)	(46)	(48) 1 (2%)	(49)
*URINARY BLADDER CALCULUS, NOS	(23) 3 (13%)	(42)	(48)	(45)
INFLAMMATION, NOS HYPERPLASIA, EPITHELIAL		1 (2%) 3 (7%)	1 (2%)	2 (4%)
NDOCRINE SYSTEM				
*PITUITARY HYPERPLASIA, NOS HYPERPLASIA, CHROMOPHOBE-CELL	(21)	(41) 3 (7%) 2 (5%)	(45)	(40)
*PITUITARY/BASOPHIL NODULE	(21) 1 (5%)	(41)	(45)	(40)
#ADRENAL LIPOIDOSIS	(25)	(43)	(48)	(48) 1 (2%)
*ADRENAL CORTEX HYPERTROPHY, FOCAL HYPERPLASIA, NOS	(25) 1 (4%)	(43) 1 (2%) 1 (2%)	(48)	(48) 1 (2%)
*ADRENAL MEDULLA NECROSIS, NOS CALCIFICATION, NOS HYPERPLASIA, NODULAR HYPERPLASIA, NOS	(25)	(43) 1 (2%) 1 (2%) 1 (2%) 6 (14%)	(48)	(48)
<pre>#THYROIC HYPERPLASIA, ADENOMATOUS HYPERPLASIA, C-CELL</pre>	(23)	(45) 1 (2%) 1 (2%)	(46)	(47) 1 (2%)
*PANCREATIC ISLETS Hyperplasia, Nos	(25)	(42) 2 (5%)	(48)	(48)
EPRODUCTIVE SYSTEM				
*MAMMARY GLAND <u>HYPERPLASIA, NOS</u>	(25)	(46) 5_(11%)	(49)	(49)

	HIGH DOSE CONTROL (UNTR) 01-0084	LOW DOSE CONTROL (UNTR) 01-0037	LOW DOSE 01-0039	HIGH DOSE 01-0090
LACTATION	7 (28%)			
*PREPUTIAL GLAND DILATATION, NOS ABSCESS, NOS HYPERPLASIA, NOS	(25)	(46) 1 (2%) 1 (2%)	(49) 1 (2%) 1 (2%)	(49)
*PROSTATE INFLAMMATION, NOS INFLAMMATION, FOCAL INFLAMMATION, SUPPURATIVE INFLAMMATION, ACUTE ATROPHY, NOS HYPERPLASIA, FOCAL HYPERPLASIA, PAPILLARY METAPLASIA, SQUAMOUS	(23) 1 (4%) 4 (17%)	(45) 21 (47%) 3 (7%) 5 (11%) 2 (4%) 5 (11%)	(47) 1 (2%) 1 (2%)	(46)
*SEMINAL VESICLE ATROPHY, NOS	(25) 1 (4%)	(46)	(49)	(49) 2 (4%)
<pre>#TESTIS CALCIFICATION, FOCAL ATROFHY, NOS ASPERMATOGENESIS HYPERPLASIA, INTERSTITIAL CELL</pre>	(24) 4 (17%) 12 (50%) 2 (8%)	(45) 2 (4%) 1 (2%) 19 (42%)	(48)	(48) 1 (2%)
*TESTIS/TUBULE DFGENERATION, NOS	(24)	(45) 6 (13%)	(48)	(48) 1 (2%)
ERVOUS SYSTEM				
#BRAIN HPMORRHAGE CALCIFICATION, FOCAL	(25) 2 (8%) 1 (4%)	(44)	(48)	(48)
SPECIAL SENSE ORGANS				
*EYE INFLAMMATION, NOS	(25)	(46)	(49) 1 (2 %)	(49)
*EYE/CORNEA ULCER. NOS	(25)	(46)	(49) 1 (2%)	(49)

TABLE C1 (CONCLUDED)

	HIGH DOSE CONTROL (UNTR) 01-0084	LOW DOSE CONTROL (UNTR) 01-0037	LOW DOSE 01-0039	HIGH DOST 01-0090
MUSCULOSKELETAL SYSTEM				
*BONF OSTEOSCLEROSIS	(25)	(46)	(49)	(49) 1 (2%)
*SKRIETAL MUSCLR CALCIFICATION, FOCAL	(25) 1 (4%)	(46)	(49)	(4 9)
*CARTILAGE,NOS CYST, NOS	(25)	(46) 1 (2%)	(49)	(49)
BODY CAVITIES				
BODY CAVITIES None				
NONE				
BODY CAVITIES NONE ALL OTHER SYSTEMS NONE				
NONE ALL OTHER SYSTEMS NONE				
NONE ALL OTHER SYSTEMS			1	

TABLE C2 SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE RATS TREATED WITH 2,5-TOLUENEDIAMINE SULFATE

	HIGH DOSE CONTROL (UNTR) 02-0084	LOW DOSE CONTROL (UNTR) 02-0037	LOW DOSE 02-0039	HIGH DOSE 02-0090
ANIMAIS INITIALLY IN STUDY ANIMALS NECROPSIED ANIMALS EXAMINED HISTOPATHOLOGICALLY**	25 23 23	50 49 49	50 50 50	50 50 50
INTEGUMENTARY SYSTEM				
NON 7			*	
RESPIRATORY SYSTEM				
*NASAL TURBINATE INFLAMMATION, SUPPURATIVE	(23)	(49)	(50)	(50) 1 (2%)
*LARYNX INFLAMMATION ACUTE AND CHRONIC INFLAMMATION, CHRONIC	(23) 1 (4%) 3 (13%)	(49)	(50)	(50)
TRACHEA HEMOFRHAGE INFLAMMATION, NOS INFLAMMATION, CHRONIC POLYP, INFLAMMATORY	(5)	(48) 9 (19%) 10 (21%) 1 (2%)	(49) 1 (2%) 1 (2%)	(49)
*LUNG/BRONCHUS BRONCHIECTASIS INFLAMMATION, NOS INFLAMMATION, CHRONIC	(23)	(49) 1 (2%) 1 (2%) 9 (18%)	(50) 1 (2%)	(50)
#LUNG/BRONCHIOLE INFLAMMATION, NOS	(23)	(49) 1 (2%)	(50)	(50)
*LUNG CYST, NOS INFLAMMATION, NOS INFLAMMATION, FOCAL INFLAMMATION, INTERSTITIAL PNEUMONIA, CHRONIC MURINE GRANULOMA, FOREIGN SODY	(23) 3 (13%) 8 (35%) 1.(4%)	(49) 1 (2%) 7 (14%) 2 (4%)	(50) 1 (2%)	(50)

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY
 NUMBER OF ANIMALS NECROPSIED
 **EXCLUDES PARTIALLY AUTOLYZED ANIMALS

	HIGH DOSE CONTROL (UNTR) 02-0084	LOW DOSE CONTROL (UNTR) 02-0037	LOW DOSE 02-0039	HIGH DOSE 02-0090
PERIVASCULITIS CALCIFICATION, FOCAL HYPERPLASIA, EPITHELIAL	1 (4%) 1 (4%)	6 (12%)		
EMATOPOIETIC SYSTEM				
BONE MAFROW Hyperplasia, Henatopoietic	(22) 1 (5%)	(48)	(49)	(45) 2 (4%)
SPLIEN HEMATOMA, NOS HEMOSIDEROSIS HYPERPLASIA, NOS HYPERPLASIA, HEMATOFOIETIC HYPERPLASIA, ERYTHROID HYPERPLASIA, PLASMA CELL HYPERPLASIA, RFTICULUM CELL HEMATOPOIESIS ERYTHROPOIESIS	(23) 1 (4%) 2 (9%) 3 (13%) 4 (17%) 3 (13%)	(49) 1 (2%) 3 (6%) 17 (35%) 1 (2%) 11 (22%)	(50) 1 (2%) 3 (6%)	(49) 1 (2%)
LYMPH NODE INFLAMMATION, NOS HYPERPLASIA, NOS PLASMACYTOSIS HYPERPLASIA, PLASMA CELL	(21)	(41) 3 (7%) 2 (5%) 3 (7%) 1 (2%)	(47)	(49)
MFDIASTINAL L.NODE HYPERPLASIA, PLASNA CELL	(21)	(4 1)	(47)	(49) 1 (2%)
RCULATORY SYSTEM				
MYOCARDIUM INFLAMMATION, NOS INFLAMMATICN, INTERSTITIAL INFLAMMATION, CHRONIC FIBROSIS DEGENERATION, NOS	(23) 1 (4%) 4 (17%)	(49) 1 (2%) 24 (49%) 5 (10%)	(50) 1 (2%) 1 (2%) 1 (2%)	(50)
PORTAL VEIN Thrombus, Mural	(23)	(49) 1 (2%)	(50)	(50)
IGESTIVE SYSTEM	·			
LIVER CONGESTION, CHRONIC PASSIVE	(23)	(49)	(50)	(49)

	HIGH DOSE CONTROL (UNTR) 02-0084	LOW DOSE CONTROL (UNTR) 02-0037	LOW DOSE 02-0039	HIGH DOST 02-0090
INFLAMMATION, CHRONIC	*************		1 (2%)	
INFLAMMATION, FOCAL GRANULOMATOU			1 (2%)	1 (2%)
FIBROSIS		1 (2%)	· • • • • • • • • • • • • • • • • • • •	
CHOLANGIOFIBROSIS	1 (4%)	(2.8)		
PERIVASCULITIS	(40)	1 (2%)		
NECROSIS, NOS		1 (2.4)	1 (2%)	
NECROSIS, FOCAL		4 (8%)	1 (2%)	1 (2%)
		2 (4%)	(2.8)	, (2%)
NECROSIS, COAGULATIVE	2 (07)		2 (1197)	1 (2%)
NETAMORPHOSIS FATTY	2 (9%)	1 (2%)	2 (4%)	1 (2/1)
BASOPHILIC CYTO CHANGE	4 (17%)	A (0.5%)		
HYPERPLASIA, NODULAR	2 (427)	1 (2%)	1 (2%)	
HYPERPLASIA, FOCAL	3 (13%)	22 (45%)	1 (2%)	
ANGIECTASIS		1 (2%)	1 (2%)	
HENATOPOIESIS			1 (2%)	
LIVER/CENTFILOBULAR	(23)	(49)	(50)	(49)
NECROSIS, DIFFUSE	(23)	(1 (2%)	())
LIVER/PERIPORTAL	(23)	(49)	(50)	(49)
METAMORPHOSIS FATTY		. ,	• •	1 (2%
BILE DUCT	(23)	(49)	(50)	(50)
INFLAMMATION, NOS		5 (10%)		
INFLAMMATION, CHRONIC		• •		1 (2%)
HYPERPLASIA, NOS	2 (9%)	27 (55%)	2 (4%)	1 (2%
PANCREAS	(22)	(46)	(50)	(49)
INFLAMMATION, NOS	• •	7 (15%)		
INFLAMMATION, INTERSTITIAL		• •		1 (2%
PERIARTERITIS			1 (2%)	
PANCREATIC DUCT	(22)	(46)	(50)	(49)
HYPERPLASIA, NOS	(22)	1 (2%)	(30)	11
·		• •		(10)
PANCREATIC ACINUS . Atrophy, Nos	(22)	(46) 2 (4%)	(50)	(49)
	(23)	(48)	(50)	(49)
STOMACH	(23)		[50]	(+)
INFLAMMATION, NOS		2 (4%)		
INFLAMMATION, FOCAL		2 (4%)	1 (20)	
PERIARTERITIS Hyperplasia, epithelial		1 (2%)	1 (2%)	
GASTRIC MUCOSA	(23)	(48)	(50)	(49)
HYPERPLASIA, NOS	(- 3)	1 (2%)	(20)	()

	HIGH DOSE CONTROL (UNTR) 02-0084	LOW DOSE CONTROL (UNTR) 02-0037	LOW DOSE 02-0039	HIGH DOSE 02-0090
*PEYERS PATCH HYPERPLASIA, NOS	(23) 4 (17%)	(47) 6 (13%)	(50)	(49)
#COLON NEMATODIASIS	(22)	(43) 3 (7%)	(48)	(48)
PARASITISM	2 (9%)			
RINARY SYSTEM				
#KIDNEY HYDRONEPHROSIS	(23)	(49) 1 (2 %)	(50)	(49)
GLOMERULONEPHRITIS, NOS INFLAMMATION, INTERSTITIAL GLOMERULONEPHRITIS, MEMBRANCUS	4 (17%)	1 (2%) 33 (67%) 1 (2%) 1 (2%)	2 (4%)	
PYELCNEPHRITIS, ACUTE INFLAMMATION, CHRONIC	1 (4%)	1 (2%)		
PYELCNEPHRITIS, CHRONIC PERIARTERITIS	1 (4%)	(())	1 (2%)	
PERIARIERITIS NEPHROSIS, NOS GLOMERULOSCIEROSIS, NOS METAMORPHOSIS PATTY	10 (43%)		1 (2%) 32 (64%) 1 (2%) 1 (2%)	22 (45%
CALCIPICATION, FOCAL	1 (4%)		. (27)	
<pre>#KIDNEY/CORTEX CYST, NOS</pre>	(23)	(49)	(50) 1 (2%)	(49)
*KIDNEY/TUBULE	(23) 1 (4%)	(49)	(50)	(49)
NECROSIS, NOS PIGMENTATION, NOS	1 (4%)		1 (2%)	
#URINARY BLADDER	(22)	(41)	(47)	(50)
INFLAMMATION, NOS Hyperplasia, epitholial		1 (2%)	1 (2%)	
NDOCRINE SYSTEM				
<pre>#PITUITARY HEMORRHAGIC CYST</pre>	(21) 1 (5%)	(43)	(48)	(43)
HYPERPLASIA, NOS	1 (5%)	2 (5%)		
HYPERPLASIA, FOCAL Hyperplasia, Chromophobe-Cell	(אכן ז	1 (2%)		
#ADRENAL LIPOIDOSIS	(23)	(46)	(50)	(48)

	HIGH DOSE CONTROL (UNTR) 92-0084	LOW DOSE CONTROL (UNTR) 02-0037	LOW DOSE 02-0039	HIGH DOSE 02-0090
HYPERTROPHY, NOS			1 (2%)	
#ADRENAL CORTEX NODULE HYPERPLASIA, NOS	(23)	(46) 1 (2%) 7 (15%)	(50)	(48)
#ADRENAL MEDULLA Hyperplasia, Nos	(23)	(46) 4 (9%)	(50)	(48)
<pre>*THYROID HYPERPLASIA, C-CELL HYPERPLASIA, FOLLICULAR-CELL</pre>	(21) 3 (14%)	(47) 1 (2%)	(48)	(49)
*PANCREATIC ISLETS Hyperplasia, Nos	(22)	(46) 1 (2%)	(50)	(49)
REPRODUCTIVE SYSTEM				
*MAMMARY GLAND GALACTOCELE	(23) 1 (4%)	(49) 5 (10%)	(50)	(50) 1 (2%)
CYSTIC DUCTS HYPERPLASIA, NOS HYPERPLASIA, FOCAL	1 (4%)	17 (35%)		1 (2%)
HYPERPLASIA, PAPILLARY HYPERPLASIA, CYSTIC FIBROCYSTIC DISEASE LACTATION	9 (39%)	1 (2%)	1 (2%) 1 (2%)	
*VAGINA HYPERTROPHY, NOS	(23)	(49)	(50) 1 (2%)	(50)
#UTERUS DILATATION, NOS HYDROMETRA	(23)	(48) 3 (6%)	(49)	(45) 2 (4%)
HENATONA, NOS INFLAMMATION, SUPPURATIVE PYOMETRA	3 (13%)	1 (2%)	1 (2%) 1 (2%)	
ABSCESS, NOS HYPERPLASIA, ADENOMATOUS	- • • • • • •	2 (4%) 5 (10%)	2 (4%)	
*CERVIX UTERI Inflammation, suppurative	(23)	(48)	(49)	(45) 1 (2%)
#UTERUS/ENDOMETRIUM INELAMMATIONNOS	(23) 1 (4 %)	(48) <u>14 (29%)</u>	(49)	(45)

	02-0084	LOW DOSE CONTROL (UNTR) 02-0037	LOW DOSE 02-0039	HIGH DOSE 02-0090
INFLAMMATION, FOCAL INFLAMMATION, SUPPURATIVE		1 (2%) 2 (4%)	8 (16%)	7 (16%
INFLAMMATION, CHRONIC	1 (4%)			
HYPERPLASIA, NOS	1 (4%)	1 (2%)	1 (2%)	<i>c</i> (13)
HYPERPLASIA, CYSTIC Hyperplasia, Adenomatous	1 (4%)	2 (4%) 1 (2%)	4 (8%)	6 (13%)
#OVARY/OVIDUCT	(23)	(48)	(49)	(45)
INFLAMMATION, NOS	1 (4%)	1 (2%)		
INPLAMMATION, ACUTE Abscess, nos	1 (4%)			
*OVA RY	(22)	(47)	(50)	(46)
CYST, NOS Abscess, Nos	3 (14%)	4 (9%)	6 (12%) 1 (2%)	
INFLAMMATION, FOCAL GRANULOMATOU FIBROSIS		1 (2%)	2 (4%)	
HYPERPLASIA, INTERSTITIAL CELL		1 (2%)	- (,	
ERVOUS SYSTEM				
BRAIN HYDROCEPHALUS, NOS	(23) 1 (4%)	(49)	(50)	(48)
H ENORRHAGF	1 (4%)			
CALCIFICATION, POCAL	1 (4%)		**	*****
PECIAL SENSE ORGANS				
NON 8				
USCULOSKELETAL SYSTEM				
NONB			* • * = = = = = = = = = = = =	
ODY CAVITIES				
*HEDIASTINUM PERIARTERITIS	(23)	(49)	(50) 1 (2 %)	(50)
+ MESENTERY PERIARTERITIS	(23)	(49)	(50) 1 (2%)	(50)
LL OTHER SYSTEMS			•	
NONE				

* NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

-

TABLE C2 (CONCLUDED)

.

.

.

	HICH DOSE CONTROL (UNTR) 02-9084	LOW DOSE CONTROL (UNTR) 02-0037	LOW DOSE 02-0039	HIGH DOSE 02-0090
PECIAL HORPHOLOGY SUMMARY				

APPENDIX D

SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MICE TREATED WITH 2,5-TOLUENEDIAMINE SULFATE

	HIGH DOSE CONTROL (UNTR) 05-0977	LOW DOSE CONTROL (UNTR) 05-0037	LOW DOSE 05-0039	HIGH DOSE 05-0089
IMALS INITIALLY IN STUDY IMALS NECROPSIED IMALS EXAMINED HISTOPATHOLOGICALLY*1	50 46 45	50 48 48	50 49 48	50 49 49
TEGUNENTARY SYSTEM				
SKIN EPIDERMAL INCLUSION CYST ULCER, POCAL INFLAMMATION, ACUTE/CHRONIC INFLAMMATION, CHRONIC FOCAL PIBROSIS ALOPECIA HYPERKERATOSIS ACANTHOSIS	(46)	(48) 1 (2%) 1 (2%)	(49)	(49) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%)
SUBCUT TISSUE NECROSIS, NOS	(46)	(48) 1 (2%)	(49)	(4 9)
SPIRATORY SYSTEM				
LUNG/BROMCHUS Inflammaticn, nos Inflammation, focal	(45)	(48) 1 (2%) 1 (2%)	(47)	(4 9)
LUNG BRONCHOPNBUNONIA, WOS INFLAMMATION, WOS	(45)	(48) 1 (2 %)	(47) 1 (2%)	(49)
INFLAMMATION, INTERSTITIAL INFLAMMATION, ACUTE FOCAL ARTERIOSCLEROSIS, NOS HYPERPLASIA, EPITHELIAL	1 (2%)	1 (2%) 14 (29%) 2 (4%)	1 (2%)	1 (2%)
LUNG/ALVZOLI HEMOBRHAGE INFLAMMATION, POCAL FIBROSIS, POCAL	(45)	(48) 2 (4%) 1 (2%)	(47)	(49) 1 (2%)

TABLE DI SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE MICE TREATED WITH 2,5-TOLUENEDIAMINE SULFATE

· · ·

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY NUMBER OF ANIMALS NECROPSIED SECLUDES PARTIALLY AUTOLYZED ANIMALS

.

	HIGH DOSE CONTROL (UNTR) 05-0077	LOW DOSE CONTROL (UNTR) 05-0037	LOW DOSE 05-0039	HIGH DOSE 05-0089
IBNATOPOIETIC SYSTEM				
*SPLEEN	(45)	(47)	(48)	(43)
INFLAMMATION, NOS	(45)	1 (2%)	(40)	(43)
PIBROSIS	1 (2%)	1 (44)		
HYPERPLASIA, NOS	(22)	2 (4%)		
HYPERPLASIA, HEMATOPOIETIC		2 (4%)		
HYPERPLASIA, ERYTHROID		2 (4%)		
HYPERPLASIA, RETICULUM CELL	3 (7%)	- • •		
HYPERPLASIA, LYMPHOID	• •	2 (4%)		
HENATOPOIESIS	1 (2%)			
ERYTHROPOIESIS				2 (5%)
*LYNPH NODE	(35)	(44)	(44)	(36)
HEMORRHAGIC CYST	• •	1 (2%)	• •	• •
INFLAMMATION, NOS		13 (30%)		
DEGENERATION, CYSTIC		1 (2%)		
HYPERPLASIA, NOS		2 (5%)		
HYPERPLASIA, HEMATOPOIETIC		1 (2%)		
HYPERPLASIA, LYMPHOID		2 (5%)		
MYELCID HETAPLASIA		2 (5%)		
*SUBMANDIBULAR L.NODE HYPEBPLASIA, PLASNA CELL	(35)	(44)	(44)	(36) 2 (6%)
447061887417 * 4004	(35)	1445	(44)	(36)
#MEDIASTINAL L.NODE	(35)	(44)	(44)	(30)
NECROSIS, NOS		1 (2%)		· .
*PANCREATIC L.NODE	(35)	(44)	(44)	(36)
INFLAMMATICH, NOS		1 (2%)	· · · · ·	
HYPERPLASIA, NOS	•		1 (2% <u>)</u>	
*MESENTERIC L. NODE	(35)	(44)	(44)	(36)
CONGESTION, NOS			3 (7%)	
HENORRHAGE		1 (2%)		
INFLAMMATION, NOS		9 (20 %)	- 6	
HYPERPLASIA, NOS	A. A.		5 (11%)	2 (6%)
#THYNUS	(19)	(34)	(32)	, (33)
NECROSIS, NOS		1 (3%)		
IRCULATORY SYSTEM		, ,	4	
#HEART/VENTRICLE	(44)	(48)	(47)	(49)
NELANIN	** **	2 (4%)	• • • •	,

	HIGH DOSE CONTROL (UNTR) 05-0077	LOW DOSE CONTROL (UNTR) 05-0037	LOW DOSE 05-0039	HIGH DOS 05-0089
<pre>#MYOCARDIUM INFLAMMATION, INTERSTITIAL FIBROSIS</pre>	(44)	(48) 2 (4%) 5 (10%)	(47)	(49)
*BLOOD VESSEL INPLAMMATION, NOS	(46)	{48) 2 (4 %)	(49)	(49)
*PULMONARY ARTERY MINERALIZATION	(46)	(48) 2 (4 %)	(49)	(49)
DIGESTIVE SYSTEM				
*SALIVARY GLAND INFLAMMATION, NOS PERIVASCULAR CUFFING	(43)	(47) 2 (4%) 1 (2%)	(47)	(45)
<pre>#LIVER HEMATONA, NOS INFLAMATION, FOCAL DEGUMERNATION, FOCAL</pre>	(45) 2 (4%)	(48)	(48) 1 (2 %)	(49)
DEGEMERATION, NOS NECROSIS, FOCAL METANORPHOSIS FATTY Hyperplasia, Nodular Hyperplasic Nodule	1 (2%) 3 (7%)	13 (27%) 3 (6%) 2 (4%)	1 (2%)	1 (2%
HYPERPLASIA, FOCAL Angiectasis Henatopoiesis		1 (2%) 1 (2%)		1 (2%
NYELOID NETAPLASIA *LIVER/FERIPORTAL INFLAMMATION, NOS	(45) 1 (2%)	1 (2%) (48)	(48)	(49)
*LIVER/HEPATOCYTES Degeneration, Nos	(45)	(48) 1 (2%)	(48)	(49)
*GALLBLADDER Inflammation, Pocal	(46)	(48) 1 (2%)	(49)	(49)
*BILE DUCT INFLAMMATICN, NOS	(46) 1 (2%)	(48)	(49)	(49)
#PANCREAS	(44)	(48)	(45)	(43)

	HIGH DOSE CONTROL (UNTR) 05-0077	LOW DOSE CONTROL (UNTR) 05-0037	LOW DOSE 05-0039	HIGH DOSI 05-0089
INFLAMMATION, FOCAL		1 (2%)		
DEGENERATION, CYSTIC		1 (2%)		
METANORPHOSIS FATTY		1 (2%)		
*PANCREATIC DUCT	(44)	(48)	(45)	(43)
HYPERPLASIA, NOS		1 (2%)		
*PANCREATIC ACINUS	(44)	(48)	(45)	(43)
HYPERTROPHY, FOCAL	•••	1 (2%)		
HYPERPLASIA, FOCAL		1 (2%)		
*STONACH	(42)	(47)	(46)	(48)
INFLAMMATION, NOS	• -•	13 (28%)	• •	
ULCER, NOS		1 (2%)		
INFLAMMATION, FOCAL		1 (2%)		
INFLAMMATION, INTERSTITIAL		1 (2%)		
PERIARTERITIS				1 (2%)
HYPERPLASIA, NOS		1 (2%)		
HYPERPLASIA, FOCAL	1 (2%)	1 (2%)		
HYPERKERATOSIS	(===)	3 (6%)		
ACANTHOSIS		3 (6%)		
#GASTRIC MUCOSA	(42)	(47)	(46)	(48)
HYPERPLASIA, FOCAL	• -•	1 (2%)		
*PEYERS PATCH	(43)	(48)	(47)	(48)
HYPERPLASIA, NOS		2 (4%)		
#ILEUN	(43)	(48)	(47)	(48)
h Eno řrhage		1 (2%)	A	
INFLAMMATION, NOS		2 (4%)		
#COLON	(38)	(45)	(43)	(46)
PARASITISM		1 (2%)		
RINARY SYSTEM				
*KIDNBY	(45)	(47)	(48)	(48)
CALCULUS, BOS	20 (44%)	-		
GLOMERULOWEPHRITIS, NOS	· · ·	e 6 (1 3%)		
INFLAMMATION, NOS	<i>.</i>	1 (2%)		• • • • •
INFLAMMATION, INTERSTITIAL	5 (11%)	23 (49%)		
INFLAMMATION, CHRONIC	1 (2%)			1 (2%)
PERIVASCULITIS	2 (4%)			والمراجع المراجع والمراجع والمراجع والمراجع

.

.

TABLE D-I (CONTINUED)

HIGH DOSE CONTROL (UNTE 05-0077	LOW DOSE CONTROL (UN 05-0037	TR) LOW DOSE 05-0039	NIGN 90 05-000
	*		
, (24)			1 (2
2 (4%)			
(45)	(47)	(48)	(4 8)
1 (2%)	• •		e - 1977 - 197
	1 (2%)		
9 (20%)			
(44)	(48)	(47)	(47)
	4 (8%)		1997 - 1997 (M. 1997)
	9 (19%)		
(20)	(#2)	46.45	1361
(30)		(4.1)	(30)
	3 (7%)		
(43)	(45)	(45)	(44)
()			
	1 (2%)		
	1 (2%)		
(43)	(45)	(45)	(4.4)
	1 (2%)		
(40)	(47)	(46)	(46)
	1 (2%)		
	1 (2%)		
	1 (2%)	an a	
(44)	(48)	(45)	(43)
	2 (4%)		
		i stati Maria	
(46)	(48)	(49)	(49)
			1 (2)
		1 (25)	
	2 (4%)		
(45)	(47) 4 (9 %)	(48)	(44)
	CONTROL (UNTE 05-0077 1 (2%) 2 (4%) (45) 1 (2%) 9 (20%) (44) (36) (43) (43) (44) (46)	CONTROL (UNTR) O5-0077 1 (2%) 2 (4%) (45) (45) (44) (44) (48) 4 (8%) 9 (20%) (44) (48) 4 (8%) 9 (19%) (44) (48) 4 (8%) 9 (19%) (43) (42) 3 (7%) 3 (7%) 1 (2%) 1 (2%)	$\begin{array}{cccccccccccccccccccccccccccccccccccc$

* NUMBER OF ANIMALS NECROPSIED

• • •

TABLE D1 (CONCLUDED)

	HIGH DOSE CONTROL (UNTR) 05-0077	LOW DOSE CONTROL (UNTR) 05-0037	LOW DOSE 05-0039	HIGH DOSI 05-0089
CALCIFICATION, POCAL			1 (2%)	
ERVOUS SYSTEM				
#CEREBRAL CORTEX MINERALIZATION	(45)	(48) 3 (6%)	(47)	(44)
PECIAL SENSE ORGANS				
NONE				
USCULOSKELETAL SYSTEM				
NONB				
ODY CAVITIES				
*ABDOHIWAL CAVITY Steatitis	(46) 1 (2%)	(48)	(49)	(49)
BECROSIS, FAT	. (24)			1 (2%)
*NESENTERY PERIARTERITIS	(46)	(48)	(49)	(49) 2 (4 %)
LL OTHER SYSTEMS				
ADIPOSE TISSUE NECROSIS, NOS				1
NECROSIS, NOS				1
	8 1		20	1

.

,¥.,

.

D-8

	HIGH DOSE CONTROL (UNTR) 06-0077	LOW DOSE CONTROL (UNTR) 06-0037	LOW COSE 06-0039	HIGH DOS1 06-0089
NNIMALS INITIALLY IN STUDY NNIMALS MISSING	50	50	50 1	50
NNIMALS NECROPSIED NNIMALS EXAMINED HISTOPATHOLOGICALLY**	46 * 46	48 47	45 43	47 -46
NTEGUMENTARY SYSTEM				
*SKIN PIERCSIS PIBROSIS, FOCAL	(46) 1 (2%) 1 (2%)	(48)	(45)	(47)
*SUBCUT TISSUF MINERALIZATION FIBROSIS	(46)	(48) 1 (2%) 1 (2%)	(45)	(47)
RESPIRATORY SYSTEM				
<pre>#LUNG/BRONCHUS INFLAMMATION, POCAL</pre>	(45)	(46) 1 (2 %)	(42)	(46)
LUNG CONGESTION, NOS	(45)	(46)	(42) 1 (2%)	(46)
INFLAMMATION, INTERSTITIAL Periarteritis	2 (4%) 1 (2%)	10 (22%)		
HYPERPLASIA, SPITHELIAL		3 (7%)		
IENATOPOIETIC SYSTEM				
#BONE NARROW MIRLCFIBROSIS	(44)	(45) 1 (2 %)	(39)	(4 1)
HYPEBPLASIA, HENATOPOIETIC		1 (22)	1 (3%)	
*SPLEEN Plasma-cell infiltrate	(43)	(46)	(42) 1 (2 %)	(42)
HYPERPLASIA, HEHATOFOLETIC HYPERPLASIA, ERYTHROID		16 (35%) 6 (13%)	• \2#/	
HYPERPLASIA, RETICULUM CELL HYPERPLASIA, LYMPHOID	2 (5%)		1 (25)	

TABLE D2 SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE MICE TREATED WITH 2,5-TOLUENEDIAMINE SULFATE

•

* NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED **EXCLUDES PARTIALLY AUTOLYZED ANIMALS

.

	HIGH DOSE CONTROL (UNTR) 06-0077	LOW DOSE CONTROL (UNTR) 06-0037	LOW DOSE 06-0039	HIGH DOSE 06-0089
HEMATOPOIESIS "RYTHROPOIESIS NYELOPOIESIS	1 (2%)	1 (2%) 1 (2%)	3 (7%) 1 (2%)	
<pre>\$LYMPH NODE CYST, NOS INFLAMMATION, 40S HYPERPLASIA, NOS RETICULOCYTOSIS HYPERPLASIA, HEMATOPOIETIC MYELOID METAPLASIA</pre>	(4 1)	(39) 1 (3%) 15 (38%) 1 (3%) 1 (3%) 2 (5%) 1 (3%)	(37)	(32)
IRCULATORY SYSTEM				
#HEART/VENTRICLE MELANIN	(45)	(46) 4 (9%)	(42)	(46)
<pre>#HYOCARDIUH CALCIFICATION, FOCAL</pre>	(45) 1 (2%)	(46)	(42)	(46)
*PULHONARY ARTERY HYPERPLASIA, NOS	(46) 1 (2%)	(48)	(45)	(47)
IGESTIVE SYSTEM				
SALIVARY GLAND INFLAMMATIOR, NOS PERIARTERITIS PERIVASCULAR CUPFING	(43)	(45) 2 (4%) 4 (9%)	(40)	(43) 1 (25)
LIVER INFLAMMATION, NOS INFLAMMATION, FOCAL BECROSIS, FOCAL CYTOPLASMIC CHANGE, NOS	(45) 1 (2%) 1 (2%)	(47) 1 (2%) 22 (47%)	(42)	(46)
HYPERPLASTIC NODULE Hyperplasia, diffuse	1 (2%)	1 (2%)		1 (2%)
ANGIECTASIS Henatopoiesis		1 (2%) 3 (6%)	2 (5%)	•
LIVER/PERIFORTAL INFLAMATION, NOS	(45) 1 (2 %)	(47)	(42)	(46)
*GALLBLADDER NOS	(46)	(48)	(45)	(47)

	CONTROL (UNTR) 06-0077	LOW DOSE CONTROL (UNTR) 06-0037	LOW COSE 06-0039	HIGH DOSE 06-0089
ILE DUCT INFLAMMATION, NOS	(46) 1 (2%)	(48) 1 (2%)	(45)	(47)
ANCREAS Inflammation, Nos	(41)	(44) 5 (11%)	(42)	(42)
INFLAMMATION, INTERSTITIAL PERIAPTERITIS		1 (2%)	1 (2%)	
ANCREATIC DUCT LYMPHOCYTIC INFLAMMATORY INFILTR	(41)	(44) 1 (2%)	(42)	(42)
TOMACH INFLAMMATION, NOS	(42)	(44) 7 (16%)	(42)	(43)
ULCER, NOS		1 (2%)		
INFLAMMATION, FOCAL		1 (2%)		
HYPERPLASIA, NOS		1 (2%)		
HYPERPLASIA, EPITHELIAL		1 (2%)		
HYPERPLASIA, ADENOMATOUS Hyperkeratosis		1 (2%) 1 (2%)		
ACANTHOSIS		1 (2%)		
ASTRIC MUCOSA	(42)	(44)	(42)	(43)
HYPERPLASIA, FOCAL		1 (2%)		
TYERS PATCH	(43)	(44)	(42)	(42)
HYPERPLASIA, NOS		1 (2%)		
NARY SYSTEM				
IDNEY	(43)	(46)	(43)	(45)
CONGESTION, NOS GLOMEBULONEPHRITIS, NOS		14 (30%)	1 (2%)	
INPLAMMATION, INTERSTITIAL	3 (7%)	16 (35%)		
GLOMERULONFPHRITIS, CHRONIC	* ()			1 (2%)
PERIVASCULITIS	4 (9%)			
IDNEY/GLOMERULUS AMYLCIDOSIS	(43)	(46)	(43)	(45)
VUITCIDADID	1 (2%)			
IDNEY/PELVIS INFLAMMATION, ACUTE/CHRONIC	(43) 1 (2%)	(46)	(43)	(45)
	(41)		(34)	(41)

	HICH DOSE CONTROL (UNTR) 96-9077	LOW DOSE CONTROL (UNTR) 06-0037	LOW DOSE 06-0039	HIGH DOSE 06-0089
HYPEFPLASIA, EPITHELIAL		10 (22%)		
<pre>\$U.BLADDER/SUBMUCOSA INFLAMMATION, CHRONIC</pre>	(4 1)	(46)	(34)	(41) 1 (2%)
NDOCRINE SYSTEM				
<pre>#PITUITARY HYPERPLASIA, POCAL</pre>	(37)	(42) 6 (14%)	(38)	(38)
#ADRENAL CORTEX NODULE	(43)	(45) 3 (7%)	(38)	(41)
<pre>#THYROID FOLLICULAR CYST, NOS INFLAMMATION, NOS</pre>	(30)	(43) 1 (2%) 1 (2%)	(36)	(34)
REPRODUCTIVE SYSTEM			******	
*MARMARY GLAND	(46)	(48)	(45)	(47)
GALACTOCELF Hyperplasia, Nos		1 (2%) 4 (8%)		
+UTERUS	(43)	(45)	(41) 2 (5%)	(42) 2 (5%)
HYDRCNETRA Inflammation, acute	4 (9%)	1 (2%)	1 (2%)	1 (2%)
ABSCESS, NOS Fibrosis		3 (7%) 1 (2%)		
#UTERUS/ENDOMETRIUM DILATATION, NOS	(43)	(45)	(41) 5 (12%)	(42)
CIST, NOS	-2 (5%)			
INFLAMMATION, NOS INFLAMMATION, SUPPURATIVE INFLAMMATION, ACUTE INFLAMMATION, ACUTE SUPPURATIVE		10 (22%) 4 (9%)	1 (2%) 1 (2%) 4 (10%)	4 (10%
HYPERPLASIA, NOS	1 (2%)	4 (9%)	• •	1
HYPERPLASIA, CYSTIC Hyperplasia, Adenomatous	35 (81%)	18 (40%) 1 (2%)	18 (44%)	28 (67%
#OVARY/OVIDUCT INFLAMATIONNOS	(43)	(45) <u>5_(11%)</u>	(41)	(42)

_ · · · · · · · ·

		06-0039	06-0089
		2 (5%)	
{41} 1 (2%)	(45) 3 (7%) 4 (9%) 1 (2%) 10 (22%) 4 (9%) 1 (2%)	(36) 2 (6%) 1 (3%) 1 (3%) 4 (11%) 1 (3%)	(39) 4 (10%) 6 (15%)
	(45)	(36) 1 (3 %)	(39)
(46)	(48) 3 (6%)	(45)	(47)
(46) 1 (2%)	(48)	(45)	(47)
	(4 1) (4 1) (4 6) (4 6) (4 6) 1 (2%)	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{c} (41) \\ 1 (25) \\ 3 (75) \\ 4 (95) \\ 1 (25) \\ 10 (225) \\ 2 (55) \\ 1 (35) \\ 4 (95) \\ 4 (95) \\ 4 (115) \\ 1 (35) \\ 4 (115) \\ 1 (35) \\ 1 (35) \\ (41) \\ (41) \\ (45) \\ (45) \\ 1 (35) \\ 1 (35) \\ 1 (35) \\ 1 (35) \\ 1 (35) \\ 1 (25) \\ 1$

TABLE D-2 (CONCLUDED)

	HIGH DOSE CONTROL (UNTR) 06-9077	LOW DOSE CONTROL (UNTR) 06-0037	LON DOSE 06-0039	HIGH DOSE 06-0089
SPECIAL KORPHOLOGY SUMMARY	i			1. J. 1.
NO LESION REPORTED	1	1	4	5
ANIEAL MISSING/NO NECROPSY AUTC/NFCROPSY/HISTO PERF	2	2	1	1
AUTO/NECROPSY/NO HISTO AUTOLYSIS/NO NECROPSY	4	1	2 4	1
# NUMBER OF ANIMALS WITH TISSUE EX * NUMBER OF ANIMALS NECROPSIED	AMINED MICROSCOPIC	ALLY		

D-14

· .

Review of the Bioassay of 2,5-Toluenediamine Sulfate* for Carcinogenicity by the Data Evaluation/Risk Assessment Subgroup of the Clearinghouse on Environmental Carcinogens

June 29, 1978

The Clearinghouse on Environmental Carcinogens was established in May, 1976, in compliance with DHEW Committee Regulations and the Provisions of the Federal Advisory The purpose of the Clearinghouse is to Committee Act. advise the Director of the National Cancer Institute (NCI) on its bioassay program to identify and to evaluate chemical carcinogens in the environment to which humans may be exposed. The members of the Clearinghouse have been drawn from academia, industry, organized labor, public interest groups, State health officials, and quasi-public health and research organizations. Members have been selected on the basis of their experience in carcinogenesis or related fields and, collectively, provide expertise in chemistry, biochemistry, biostatistics, toxicology, pathology, and epidemiology. Representatives of various Governmental agencies participate as ad hoc members. The Data Evaluation/Risk Assessment Subgroup of the Clearinghouse is charged with the responsibility of providing a peer review of reports prepared on NCI-sponsored bioassays of chemicals studied for carcinogenicity. It is in this context that the below critique is given on the bioassay of 2,5-Toluenediamine Sulfate for carcinogenicity.

Although a carcinogenic response was not demonstrated, the reviewer said that the evidence was suggestive that the compound may have a carcinogenic potential. He recommended that it be considered for retest. In his critique, he noted several experimental flaws, including the use of animals from different shipments, the conduct of the subchronic study in a different mouse strain than used in the chronic phase, and the start of the high dose rats on test some months after the initiation of the low dose animal group. The reviewer said the compound warranted further testing because of the experimental design and study conduct deficiencies, as well as the fact that 2,5-Toluenediamine Sulfate had been shown to be positive in the Ames assay. The reviewer moved that the report on the bioassay of 2,5-Toluenediamine Sulfate be accepted as written but that the compound be considered for retest. The motion was approved without objection.

Clearinghouse Members present:

Arnold L. Brown (Chairman), Mayo Clinic
Paul Nettesheim, National Institute of Environmental Health Sciences
Verne Ray, Pfizer Medical Research Laboratory
Verald K. Rowe, Dow Chemical U.S.A.
Michael B. Shimkin, University of California at San Diego
Louise Strong, University of Texas Health Sciences Center

* Subsequent to this review, changes may have been made in the bioassay report either as a result of the review or other reasons. Thus, certain comments and criticisms reflected in the review may no longer be appropriate.

AU.S. GOVERNMENT PRINTING OFFICE: 1978-260-899/3201

ı

DHEW Publication No. (NIH) 78-1381

•

-